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Abstract: Background: In children with uncontrolled asthma prescribed 
low-dose inhaled corticosteroids (ICS), various step-up options are 
available: fixed-dose combination ICS/long-acting β2-agonist (FDC); 
increasing ICS dose; adding leukotriene receptor antagonist (LTRA). 
However, evidence of their relative effectiveness is limited. 
Objective: To compare the effectiveness of step-up to FDC in children 
with asthma versus increase ICS dose, or LTRA. 
Methods: This matched cohort study used UK primary-care databases to 
study children prescribed their first step-up treatment to FDC, increase 
ICS dose, or LTRA. A year of baseline data was used for matching and 
identifying confounders. Outcomes over the following year were examined. 
The primary outcome was severe exacerbation rate; secondary outcomes 
included overall asthma control (no asthma-related admissions/hospital 
attendances/oral corticosteroids or antibiotics prescribed with a 
respiratory review, and average prescribed salbutamol <200 µg/day). 
Results: There were 971 matched pairs in the FDC and increase ICS dose 
cohorts (59% male; mean age 9.4 years), and 785 in the FDC and LTRA 
cohorts (60% male; mean age 9.0 years). Exacerbation rates in the outcome 
year were similar between FDC and increase ICS dose (adjusted incidence 
rate ratio (IRR), 1.09 [0.75-1.59]) and FDC and LTRA (IRR, 1.36 [0.93-
2.01]). Children prescribed increased ICS dose and LTRA had significantly 
reduced odds of achieving overall asthma control, compared with FDC (odds 
ratios 0.52 [0.42-0.64] and 0.53 [0.42-0.66], respectively). 
Conclusion: For children stepping-up asthma treatment, FDC is as 
effective as increased ICS or LTRA in reducing the rate of severe 
exacerbations, but more effective in achieving asthma control. 
 
 
 
  
Response to editors and reviewers comments 
 
 
EDITOR'S SPECIFIC COMMENTS: 
Thank you for considering JACI: In Practice for your research submission. Your manuscript has been 
favourably reviewed. In addition to addressing the reviewers comments please consider the 
following in your revision: 
 
1. Please comment on the limitations of not matching based on demographic (ethnicity, SES) 
and comorbidities (obesity) that if not balanced could affect outcomes. 
 
Response: We agree that these limitations warrant comment and have added to the discussion L381-
383. 
 
 
2. Several recent publications deserve inclusion:  
(a) Stempel DA, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. 
N Engl J Med. 2016;375:840-9. 
(b) Stempel DA, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone 
Alone. N Engl J Med. 2016;374:1822-30. 
(c) Turner S, et al. Long-Acting <beta>-Agonist in Combination or Separate Inhaler as Step-Up 
Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. J Allergy Clin 
Immunol Pract. 2016, in press. j.jaip.2016.06.009 
 
Response: We agree these recent publications deserve citation and have included them as reference 
12, 13 and 20 respectively. 
 
 
 
COMMENTS FROM REVIEWER #1: 
The authors compare the effectiveness of the three step-up regimens in children with uncontrolled 
asthma who are prescribed inhaled corticosteroids in a matched cohort study.  The matching 
algorithm is clearly described by the authors and appears appropriate for the questions being asked.  
The statistical analyses are also clearly described and appropriate for the questions being asked.  I 
have no suggestions for the authors. 
 
Response: The authors thank the reviewer for their positive comments. 
 
 
 
COMMENTS FROM REVIEWER #2: 
This is a novel approach to provide better supporting evidence for the move to Step 3 in asthma 
guidelines. The data are interesting and relevant. There are limitations to the approach, balanced by 
the volume of data made available. Comments as below. 
 
INTRODUCTION: 
1. Line 96: The current BTS guidelines do not advice addition of LABA as FDC as the first step up 
option - in the historical context of this report it would be important to reflect the advice 
provided to practitioners at that time rather than most recent updates.  
 
Responses to Comments
Response: We agree that the current guidelines do not specifically recommend the use of LABA as 
FDC though state that “In clinical practice, however, it is generally considered that combination 
inhalers aid adherence and also have the advantage of guaranteeing that the LABA is not taken 
without the ICS” we have therefore deleted “as FDC” from the sentence (line 85). We have also added 
comment to the introduction with regard to this and why we chose to compare the addition of LABA 
as FDC (L139-144) 
 
 
2. The group can now quote their JACI 2016 paper identifying FDC as a better option than 
separate inhalers as a rationale for looking at FDC.  
 
Response: We have now quoted the recent JACI paper (reference 20) in the introduction and 
discussed why we chose to compare the addition of LABA only using FDC rather than separate 
inhalers. (L139-144) 
 
 
3. Line 116. 'Near impossible' is hyperbole. Other health systems may manage this type of 
study effectively. Remove. 
 
Response: We agree, we have removed “near Impossible”. 
 
 
METHODS: 
4. Line 164. Please provide evidence of 'well-validated' 
 
Response: We have added a reference to justify this statement (Reference 23) 
Hansell A, Hollowell J, Nichols T, et al. Use of the General Practice Research Database (CPRD) for 
respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). 
Thorax 1999;54:413-9 
 
 
5. Line 181. Was there a minimum or maximum ICS dose at baseline? i.e. what rules were there 
to exclude those managed on inappropriately low or high doses (i.e. doubling from 50mcg 
beclomethasone once daily to twice daily OR 400mcg BD to 800mcg BD not in keeping with 
guideline recommendation to add on at lower doses).  
 
Response: There were no minimum or maximum ICS doses specified at baseline as this was a real-life 
study and therefore treatment choice was entirely down to the individual prescriber. However, 
subjects were matched at baseline for ICS dose and therefore numbers who may have been 
“inappropriately managed” on low or high doses of ICS should have been equally distributed between 
the comparison groups. It is also of note that the mean daily dose of ICS prior to Index date was 
around 370 mcg of beclomethasone equivalent, the median dose for all 4 groups was 400mcg and 
IQR for all 4 groups was 200-400. We have added this data to Table 1 for clarity (previously only 
average daily ICS dose over the baseline year was in Table 1). We have also now made reference to 
this in the results section L251-256. In addition Table E1 and E2 show numbers of subjects in the 
matched cohorts within daily ICS dose ranges; there were no subjects in any of the cohorts with daily 
ICS dose <150mcg, 2% of  each cohort of FDS vs Increased ICS and 6% of each cohort of FDS vs LRTA 
with doses >500mcg/day. 
 
 
 
RESULTS: 
6. Lines 253-259. The group adequately explain areas in which the groups do not match - but 
should return to this in the discussion. LTRA would more typically be prescribed in those 
with rhinitis and this may have influenced outcomes. Those prescribed FDC were on lower 
doses on ICS at outset (possibly better controlled) and had more regular review in primary 
care (also associated with better control).  
 
Response: We have added to the discussion expanding the strengths and limitations section with 
regardto the above and other potential bias L367-383. We have also added the mean daily dose at 
time of Step-up (Index date) to table 1, as this is not significantly different between the groups and 
have clarified that Average daily ICS dose relates to the average over the whole baseline year. 
 
 
7. Table E3 highlights the assessment of prescription adherence. It would be helpful reference 
to adherence be made in the main text linking to this table.  
 
Response: We agree and have mentioned this in the text L273-274. 
 
 
DISCUSSION: 
8. Line 315. This and previous reports identify individual response to options available at Step 
3. Is there evidence to suggest that those who move across steps (i.e. option hopping) gain 
stability that negates the need to step up? 
 
Response: It is clear from the large randomised double blind crossover study (Lemanske et al 2010) 
that this is likely to be the case; although more individuals are likely to respond to FDC than the other 
two options. Our study supports the RCT findings that children appear to be more likely to gain 
control and treatment stability on FDC, but that children can improve on the other options with all 
children having fewer exacerbations having moved to one of the treatment options at Step3.This 
study looked at only the first step-up(either a ≥50% increase in ICS dose, switched to a FDC, or had a 
LTRA added) and so unfortunately we cannot comment as to whether option hopping negated the 
need to step-up. 
 
 
9. Line 357. 'We believe' - pls support this statement or remove. 
 
Response: We have removed the sentence “We believe the current study complements shorter-
term, smaller randomized controlled trials, and shows the value of real-life research for 
understanding asthma therapies in children.” 
 
 
10. Line 365. Should also discuss influences of physician behaviour and patient choices.  
 
Response: We have added to the discussion and this is discussed in L364-370. 
 
 
11. Practice changes with time. Some primary care physicians will be slower to change practice 
than others - that may suggest a less progressive approach to patient care. Table E1 
identifies that FDC is more commonly used more recently. By matching the group may be 
comparing more progressive practices (with regular patient review) with practices that are 
slower to change. Please discuss. 
 
Response: We agree and have added this discussion point L373-380. 
 
 
CONCLUSIONS: 
12. Lines 402 and 404. The group have explained in the discussion that they do not know why 
therapies were increased and have assumed that 'control was felt to be inadequate' (line 
385). The conclusion that these children were uncontrolled on low-dose ICS is therefore 
incorrect - both as they cannot state that the reason for step up was lack of control and also 
because the study was not limited to those stepping up from low dose ICS (some were on 
>500mcg/day ICS). Please revise the conclusions to accurately reflect what the study was 
able to demonstrate - rather than what it was hoped it might be able to demonstrate. 
 
Response: In the discussion of the version submitted we acknowledged that we did not directly 
capture asthma control and instead relied on a surrogate of control (i.e. prescription). We have 
added to the discussion with regard to why therapies may have been stepped up (L398-402). We 
believe  that children were likely to have been perceived as being poorly controlled by their doctor. 
SABA use averaged over 12 months was 2.5 puffs per day; it is quite likely that this was not steady 
throughout the 12 months, but sporadic. We feel it is unlikely that general practitioners increased 
treatments and the cost of treating a patient without reason. In the results section we have added 
data with regard to ICS dose (data previously only presented in Tables). Only 3.9% of all children were 
on >500mcg/day of beclomethasone or equivalent. Therefore the overwhelming majority of this 
cohort was on low dose ICS. We have changed the sentence in the conclusion to read “The findings of 
our real-life study suggest that the three main step-up treatments have beneficial effects in children 
who are stepped up from low/moderate-dose ICS, and that the differential effect of any of these 
treatments is small.” rather than “The findings of our real-life study suggest that the three main 
step-up treatments have beneficial effects in children who are stepped up from low/moderate-dose 
ICS, and that the differential effect of any of these treatments is small.”  which we hope will clarify 
the situation (L420). 
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Clinical Implications 40 
Although guidelines advise a first choice for step-up in children with uncontrolled asthma, 41 
fixed-dose ICS/long-acting β2-agonists (FDC), increased ICS dose, or added leukotriene 42 
receptor antagonists all reduce severe exacerbation rates, but FDC may also improve 43 
asthma control. 44 
 45 
Capsule Summary 46 
Fixed-dose combination inhalers were as effective in reducing severe exacerbations over 12 47 
months for children stepping-up asthma therapy, as increasing inhaled corticosteroid dose or 48 
adding a leukotriene receptor antagonist. 49 
  50 
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ABSTRACT 51 
Background: In children with uncontrolled asthma prescribed low-dose inhaled 52 
corticosteroids (ICS), various step-up options are available: fixed-dose combination 53 
ICS/long-acting β2-agonist (FDC); increasing ICS dose; adding leukotriene receptor 54 
antagonist (LTRA). However, evidence of their relative effectiveness is limited. 55 
Objective: To compare the effectiveness of step-up to FDC in children with asthma versus 56 
increase ICS dose, or LTRA. 57 
Methods: This matched cohort study used UK primary-care databases to study children 58 
prescribed their first step-up treatment to FDC, increase ICS dose, or LTRA. A year of 59 
baseline data was used for matching and identifying confounders. Outcomes over the 60 
following year were examined. The primary outcome was severe exacerbation rate; 61 
secondary outcomes included overall asthma control, derived from databases (no asthma-62 
related admissions/hospital attendances/oral corticosteroids or antibiotics prescribed with a 63 
respiratory review, and average prescribed salbutamol <200 µg/day). 64 
Results: There were 971 matched pairs in the FDC and increase ICS dose cohorts (59% 65 
male; mean age 9.4 years), and 785 in the FDC and LTRA cohorts (60% male; mean age 66 
9.0 years). Exacerbation rates in the outcome year were similar between FDC and increased 67 
ICS (adjusted incidence rate ratio (IRR), 1.09 [0.75–1.59]) and FDC and LTRA (IRR, 1.36 68 
[0.93–2.01]). Increased ICS and LTRA significantly reduced odds of achieving overall 69 
asthma control, compared with FDC (odds ratios 0.52 [0.42-0.64] and 0.53 [0.42-0.66], 70 
respectively) – this was driven by reduced SABA use. 71 
Conclusion: FDC is as effective as increased ICS or LTRA in reducing severe exacerbation 72 
rate, but more effective in achieving asthma control. 73 
 74 
 75 
  76 
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INTRODUCTION 77 
Asthma is the commonest chronic disease in childhood, affecting about 1 in 11 children 78 
in the UK (1). Although most children are well-controlled on low-dose inhaled corticosteroids 79 
(ICS), some will still experience symptoms and exacerbations, and physicians will 80 
recommend a step-up in treatment (2). Current guidelines offer a number of different choices 81 
to physicians, including increasing the dose of ICS and addition of either long-acting beta-82 
agonists (LABA) or leukotriene receptor antagonists (LTRA). Most guidelines, however, tend 83 
to put forward a first choice at this step: The British Thoracic Society guidelines advise the 84 
addition of LABA as the first step-up option (3); the Global Initiative for Asthma (GINA) 85 
recommends prescribing increased doses of ICS (4).   86 
The reason for these differences in guidance is that research on the comparative 87 
effectiveness of pediatric step-up therapies is limited. In the last few years, the evidence for 88 
which step-up treatment may be best has increased (5-10); in part, by the publication of a 89 
large randomized crossover trial evaluating differential responses over 16 weeks to three 90 
step-up strategies in 182 children aged 6–17 years with uncontrolled asthma on low-dose 91 
ICS (5). However, despite these important recent publications, a Cochrane review of the 92 
evidence published in 2014 still concluded that owing “to the paucity of pediatric trials,” the 93 
authors were “unable to draw firm conclusions about the best adjunct therapy in children” 94 
(11). In addition, until recently, controversy regarding the safety of LABAs may also impacted 95 
on choice (12,13) 96 
Notably, a large multicenter randomized controlled trial in the UK investigating 97 
whether adding LABA or LTRA to low-dose ICS in children could reduce the number of 98 
exacerbations closed early because of lack of recruitment (14). Despite increasing the 99 
recruitment time, only 63 children were randomized in this study from a target sample size of 100 
450. Recruitment proved difficult in the main because children eligible for the trial were 101 
already prescribed add-on therapy. Consequently, no firm conclusions regarding the study 102 
medications could be drawn. 103 
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Although more evidence is required, large randomized controlled trials not only are 104 
expensive and time-consuming to conduct, but also can be difficult to recruit for. The 105 
strengths of “real-world” studies have been highlighted in the “Brussels Declaration” (15). A 106 
Respiratory Effectiveness Group (REG) study was the first to report on initial step-up 107 
episodes in over 10,000 children in the UK, and the first to describe the clinical 108 
characteristics of children who received different step-up options (16). Another REG 109 
publication compared the effectiveness of extrafine-particle versus fine-particle ICS for 110 
children initiating or stepping-up ICS therapy and ICS dose step-up with LABA (17). “Real-111 
world” data about the clinical outcomes of asthma therapy can provide new information and 112 
hypotheses and complement data from controlled trials (18).  113 
The aim of this large population-based observational study was to compare the 135 
effectiveness of step-up therapies from low-dose ICS in a real-life pediatric population. In 136 
two matched cohorts, we compared the effect of a change to fixed-dose combination (FDC) 137 
versus an increase in ICS dose, and a change to FDC versus add-on LTRA, on asthma 138 
exacerbations and asthma control in the following year. We chose to compare the addition of 139 
LABA as a FDC inhaler rather than separate add on LABA as current global GINA guidelines 140 
recommend the use of combination inhalers (4), our own national guidelines recommend 141 
FDC as the optimal means of adding LABA (19) and we have recently published data from a 142 
similar historical cohort indicating that better asthma control was achieved with FDC inhalers 143 
than with separate inhalers (20). 144 
 145 
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METHODS 146 
Study design  147 
This was a historic observational database study of step-up therapy in children with 148 
asthma, consisting of a baseline year for matching and identifying potential baseline 149 
confounders, preceding the date on which patients received treatment step-up (index date), 150 
followed by an outcome year for evaluating comparative effectiveness (Figure E1). 151 
 152 
Data sources and permissions 153 
Two UK primary care databases were used to source medical and prescribing data, 154 
which include approximately 15% of UK children, and have previously been described in 155 
detail (16,17). Firstly, the Clinical Practice Research Datalink (CPRD), is the world’s largest 156 
database of de-identified records from primary care, and includes longitudinal data from 157 
more than 5 million active medical records from across the UK (21,22). It is a well-validated 158 
database that has been used in numerous observational studies (23). Secondly, the 159 
Optimum Patient Care Research Database (OPCRD) is a quality-controlled primary care 160 
research database that contains anonymous routine medical record data and patient 161 
reported outcomes from over 550 practices in the UK (24). Data was available from 1st 162 
January 1999 through April 2012 for the CPRD, and to December 2012 for the OPCRD. 163 
Patient records were checked to avoid duplication of individuals in the analyses. 164 
The study was conducted to standards recommended for observational research (25) 165 
and is registered with the European Network of Centres for Pharmacoepidemiology and 166 
Pharmacovigilance (study registration: ENCEPP/SDPP/10483). Data use was approved by 167 
the Independent Scientific Advisory Committee of the CPRD and the Trent Multi-Centre 168 
Research Ethics Committee. The study protocol was approved by the Anonymized Data 169 
Ethics Protocols and Transparency (ADEPT) committee, the independent scientific advisory 170 
committee for the OPCRD.  171 
 172 
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Study population 173 
Included all children were aged 5–12 years with a diagnostic code for asthma or ≥2 174 
asthma prescriptions, or both, in the previous 12 months, were receiving ICS at baseline, 175 
and who had a ≥50% increase in ICS dose, switched to a FDC, or had a LTRA added at the 176 
index date. Included children were registered in the database for at least one year prior to 177 
and following the index date, and had to have received at least one asthma prescription in 178 
addition to the index date prescription during the outcome year. Children were excluded if 179 
they had ever received a diagnosis of any chronic respiratory disease other than asthma, 180 
maintenance oral corticosteroid therapy, multiple step-up therapies at the index date, or a 181 
previous add-on therapy.  182 
 183 
Outcomes 184 
The primary outcome was the number of severe asthma exacerbations in the year 185 
following the index date. Severe asthma exacerbations were defined according to American 186 
Thoracic Society/European Respiratory Society (ATS/ERS) criteria, as an asthma-related 187 
emergency or hospitalization or oral corticosteroids with evidence of respiratory review (26).  188 
Secondary outcomes included: 189 
1. Risk-Domain Asthma Control: No emergency or hospital attendance for asthma-related 190 
events; no acute course of oral corticosteroids or antibiotics with evidence of respiratory 191 
consultation.  192 
2. Overall Asthma Control: Risk-Domain Asthma Control and average daily prescribed dose 193 
of ≤200 μg/day salbutamol or ≤500 μg/day terbutaline (equivalent to ≤2 puffs daily of reliever 194 
medication).  195 
3. Treatment stability: Risk-Domain Asthma Control and no preventer treatment change in 196 
the year following the index date.  197 
4. Acute Respiratory Events: Defined as the total number per patient, where an event is 198 
defined as asthma-related emergency or hospitalization or, oral corticosteroids with evidence 199 
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of respiratory review or, antibiotics prescribed with evidence of respiratory review, in the year 200 
following the index date. 201 
Other secondary outcomes including SABA use, prescriptions for oral thrush, and asthma-202 
related hospitalizations, are defined in detail in the Online Repository.  203 
 204 
Statistical analysis 205 
Eligible children from the increase ICS dose and LTRA cohorts were separately 206 
matched (1:1) on key demographic and asthma-related characteristics during the baseline 207 
year to children from the FDC cohort. Matching variables were agreed by the steering 208 
committee a priori as the variables most likely to be associated with asthma outcomes and 209 
therefore potentially confound the results. The final matching variables were: 210 
 211 
1. Index date (+/- 3 years) 212 
2. Age (in years) 213 
3. Any severe asthma exacerbations during the baseline year  214 
4. Prior ICS dose (0-150, 151-250, 251-500, >500 in budesonide equivalent μg doses) 215 
5. Average short-acting β-agonist (SABA) daily doses during the baseline period (0, 1-216 
200, or ≥201 μg salbutamol or equivalent) 217 
Baseline characteristics and outcome variables for unmatched patients were compared 218 
using Chi-square or Mann Whitney tests and, for matched patients, conditional logistic 219 
regression. 220 
The total number of asthma exacerbations and acute respiratory events in the outcome 221 
year were compared between treatment cohorts separately using negative binomial 222 
regression to estimate the incidence rate ratio (IRR) for exacerbations relative to the FDC 223 
group. General estimating equations were used to account for the correlation within matched 224 
pairs. The models used empirical standard errors (to calculate 95% confidence intervals [CI]) 225 
and were adjusted for baseline confounders (27). The other secondary outcomes were 226 
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compared relative to the FDC group using conditional logistic regression models to estimate 227 
adjusted odd ratios (OR) and 95% CIs. 228 
For all multivariable models, variables showing a trend towards a difference (P < 0.10) 229 
between the matched treatment cohorts at baseline were included as potential confounding 230 
factors along with any strongly predictive variables of the outcome (see Online Repository). 231 
Variables were examined for collinearity and clinical importance and were then removed in a 232 
backwards stepwise procedure, retaining confounding variables with P < 0.1. Analyses were 233 
performed using IBM SPSS Statistics Version 19 (SPSS Statistics, IBM, Somers, NY, USA), 234 
and SAS versions 9.2 and 9.3 (SAS Institute, Marlow, Buckinghamshire, UK). Statistical 235 
significance was defined as P < 0.05.  236 
 237 
RESULTS 238 
Participants 239 
The inclusion/exclusion criteria resulted in 1390 children being selected into the FDC 240 
cohort, 9192 into the increase ICS dose cohort and 1275 into the LTRA cohort (Table E1 241 
and Table E2). Following matching, there were 971 matched pairs in the FDC versus 242 
increase ICS dose analysis (Figure E2), and 785 matched pairs in the FDC versus LTRA 243 
analysis (Figure E3). Table E1 and Table E2 in the Online Repository show the impact of 244 
matching at baseline on unmatched and matched cohorts for demographic variables and 245 
potential confounders. 246 
Children were well-matched on age, sex and comorbidities, although rhinitis was more 247 
common in children stepped-up to LTRA than FDC (Table I). Acute respiratory events and 248 
antibiotics with respiratory consult were more common, and asthma GP consultations less 249 
common, in the LTRA group. Average daily dose of ICS in the baseline year was 250 
significantly lower in those children who were stepped-up to FDC compared with increase 251 
ICS dose (175 µg versus 203 µg) and with LTRA (176 µg versus 188 µg). However, ICS 252 
dose at time of index date was similar between the comparison groups. Overall, no child was 253 
on less than 150µg/day (beclomethasone equivalent) ICS and only 3.9% of all children were 254 
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on >500µg/day (Table E1 & E2). Children who stepped-up to FDC had more GP 255 
consultations for asthma than other groups at baseline.  256 
 257 
Increase ICS dose versus FDC  258 
The percentage of children experiencing one or more exacerbations fell from more 259 
than 11% during baseline to 6% during the outcome year in both cohorts. In the adjusted 260 
analysis, there was no significant difference in exacerbation rates for patients increasing ICS 261 
dose compared with those stepping-up to an FDC (IRR=1.09 [95% CI, 0.75–1.59]; P = 0.09, 262 
Figure I). Similarly, there was no difference in the odds of achieving risk-domain asthma 263 
control (OR=0.91 [95% CI, 0.71–1.16]; P = 0.44). However, children with increased ICS dose 264 
compared with those switching to FDC had significantly lower odds of achieving treatment 265 
stability (0.43 [95% CI, 0.35–0.53]; P < 0.001), and significantly lower odds of achieving 266 
overall asthma control (0.52 [95% CI, 0.42–0.64]; P < 0.001), likely driven by average daily 267 
SABA dose. Patients in the increased ICS dose cohort had a higher mean daily SABA dose 268 
than those in the FDC cohort (315 vs. 233µg; Table II). Similar to the findings at baseline, 269 
asthma GP consultations were still significantly higher in children who stepped-up to FDC 270 
compared with those increasing ICS, though both groups had reduced consultation rates 271 
(Table II). Further outcome differences (e.g. estimates of adherence, ED visits, spacer 272 
prescription) are reported in Table E3, Online Repository. 273 
 274 
Add-on LTRA versus FDC  275 
The percentage of children experiencing one or more exacerbations fell from 13% in 276 
both cohorts during the baseline year to 6% and 8% in the FDC and LTRA cohorts, 277 
respectively, during the outcome year. In adjusted analysis, there was no significant 278 
difference in the rate of severe exacerbations for children stepping-up with add-on LTRA 279 
compared with changing to an FDC (IRR=1.36 [95% CI, 0.93–2.01]; P = 0.12; Table II, 280 
Figure II). Patients adding LTRA had lower odds of achieving risk-domain asthma control, 281 
(OR=0.77 [95% CI, 0.60–1.00]; P = 0.05) and overall asthma control (OR=0.53 [95% CI, 282 
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0.42–0.66]; P < 0.001; Figure II), compared with those switching to FDC, again likely driven 283 
by average daily SABA dose. Patients prescribed LTRA had significantly higher average 284 
daily SABA dosage, compared with FDC (315mg vs 232mg, p<0.001; Table II). Further 285 
outcome differences are reported in Table E3, Online Repository. 286 
 287 
DISCUSSION 288 
Main findings 289 
In this historical, matched cohort study, we found no significant differences in the 290 
year following step-up between either change to FDC versus increased doses of ICS or, 291 
change to FDC versus add-on LTRA, in either the number of, or rate of, severe asthma 292 
exacerbations (ATS/ERS definition). All cohorts achieved a reduction in the number of 293 
exacerbations in the year following step-up. Children changing to FDC were more likely to 294 
achieve asthma control compared to step-up with add-on LTRA or with increased ICS dose. 295 
Children changing to FDC were more likely to achieve treatment stability than those who 296 
increased their ICS dose. Perhaps not surprisingly, those children who stepped-up to FDC 297 
had less average daily SABA use than either of the two comparison groups. This is partly 298 
reflected in the overall asthma control findings. These results were observed after 299 
adjustment for all relevant factors in the data set.  300 
 301 
Interpretation of findings 302 
Very few studies comparing the addition of LABA to ICS with increased doses of ICS 303 
have investigated exacerbations requiring oral corticosteroids as an outcome (5,6,9,10), and 304 
even fewer compared this outcome for the addition of LABA to ICS or LTRA with ICS (5), 305 
despite exacerbations being highlighted as a core outcome for asthma trials in children (28). 306 
None of these studies use exacerbations requiring oral prednisolone as the primary outcome 307 
of the study, although one large triple crossover study of 182 children included 308 
exacerbations requiring oral corticosteroids along with number of asthma control days and 309 
forced expiratory volume in the first second of expiration (FEV1) as a composite score for the 310 
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primary outcome (5). In this crossover study, more children were likely to respond better to 311 
addition of LABA to ICS than either increased ICS or LTRA, although there was considerable 312 
individual subject heterogeneity in the differential responses to the 3 therapies. Studies 313 
reporting exacerbations as secondary outcomes report very few numbers of exacerbations 314 
and therefore results are difficult to interpret (6, 9, 10). A recent Cochrane review meta-315 
analysis comparing exacerbation rates requiring oral steroid use in those adding LABA to 316 
ICS and those with increased ICS dose, included just 3 studies (6,9,10) (approximately 290 317 
children per group), and found that there was no significant difference in exacerbation rate 318 
between either group (odds ratio, 1.69 [95% CI, 0.85–3.32]) (29).  319 
Severe asthma exacerbations are relatively rare events, albeit important to patients 320 
and costly to the health service. Very large studies with a long follow-up period are required 321 
to investigate the effect of interventions on exacerbation rates. Real-life studies are ideally 322 
placed to answer such a research question, as typically they are of sufficient size and 323 
duration to assess the impact of exacerbations on health outcomes (30). However, even in 324 
this large real-life study with a 12-month follow-up period, exacerbation rates were very low. 325 
We found no significant difference between the different step-up treatments in exacerbation 326 
rate. All step-up treatments assessed in this study were associated with reduced 327 
exacerbation rates, suggesting all are effective in reducing exacerbations. 328 
Randomized controlled trials have assessed asthma control in different ways, mostly 329 
with the use of symptom diaries for differing periods of time, documenting daytime and 330 
nighttime symptoms and reliever medication use. Two trials reported no difference in control 331 
between the groups (6,9); one reported better asthma control in the increased ICS group 332 
compared with the addition of LABA group (10) and the other reported, in the form of a 333 
composite score, better outcomes in the addition of LABA group (5). In this real-life 334 
observational study, asthma control cannot be measured in the same way as in prospective 335 
trials. However, the results of our study suggest that control was more likely to be achieved 336 
in children who were stepped-up to FDC, rather than by increasing ICS or by adding LTRA. 337 
When comparing FDC with increased ICS or addition of LTRA, overall asthma control was 338 
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about twice as likely to be achieved, indicating that those individuals stepped-up to FDC had 339 
fewer unscheduled visits and less SABA usage. Although the differential effect between 340 
these step-up changes appears small, this large real-life study complements data from the 341 
largest of the randomized controlled trials cited in this study (5), and supports those 342 
guidelines which advise the addition of LABA as FDC as the first step-up option (3), rather 343 
than those which advise prescribing increased doses of ICS(4).      344 
 345 
Strengths and Limitations 346 
A major strength of our study is the size, which was considerably larger than the 347 
Cochrane meta-analysis (29). No prospective sample size calculation was estimated for the 348 
study; alternatively, we included all eligible children in the databases from 1st January 1999 349 
who had the required data, to maximize study size. Data prior to 1999 was not extracted 350 
since LTRA and FDC inhalers were not licensed for use in the UK until 1998 and 1999, 351 
respectively. Data were extracted from well-maintained databases containing medical 352 
records of approximately 15% of all UK children. Further, approximately 62% of those who 353 
stepped-up to LTRA, and 70% of those stepped-up to FDC, were analyzed, although not all 354 
children who stepped-up were selected. However, we believe that the matched children in 355 
this study were largely representative of those who initiate step-up within primary care 356 
settings in the UK. In addition, the study follows children for a full year following step-up.  357 
We conducted a thorough matching process (25), resulting in cohorts with similar 358 
baseline characteristics and asthma severity. We adjusted for additional potential 359 
confounding factors, and collected and analyzed follow-up data for a full year after the index 360 
date. However, we cannot exclude the possibility of residual confounding in this study; for 361 
example, the LTRA cohort had more antibiotics but fewer primary care consultations in the 362 
baseline year, perhaps indicating more unstable asthma or different consulting behavior. 363 
There was however, no evidence of significant difference in control at baseline (% of children 364 
who achieved Risk-domain and Overall control similar in baseline year). The LRTA cohort 365 
also had a higher incidence of rhinitis, which may have impacted on the severity of asthma 366 
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symptoms but also may have affected physician choice of step-up treatment. We addressed 367 
this where possible, for example, investigating antibiotics and primary care consultations as 368 
confounders in the multivariate models; they were used as adjusting variables in several of 369 
the outcome models, (where  thought to be important). It is also of note that when examining 370 
the year of Index date, patients who stepped up to FDC tended to have later Index dates 371 
than those stepped up to increased ICS. This is probably likely to be due to the fact that 372 
more FDC was used as time progressed as the practitioners became more familiar with its 373 
use (license only granted in children in 1999). However, we cannot reject the possibility that 374 
this may have caused bias within our study; perhaps physicians who adopted the approach 375 
of prescribing this shortly after being granted license were also more progressive in other 376 
ways and managed their patients differently.  377 
We were not able to match on BMI as much of this data was missing from the 378 
dataset, and this may have introduced bias. Socio-economic status and ethnicity was not 379 
available to us. This may also have resulted in bias in our sample. Some incomplete patient 380 
records will have led to some individuals being excluded from this study, which may have 381 
introduced some selection bias. 382 
Conventional methods of measuring asthma control include diary cards, daily SABA 383 
use, and the Asthma Control Test (31,32), but none are considered the “gold standard.” Due 384 
to the historic nature of this study and its large size, we used indirect, surrogate measures of 385 
control derived from accurate markers of healthcare use (both primary and secondary) for 386 
respiratory conditions, prednisolone use, prescription of antibiotics and SABA use; but it is 387 
recognized that some of these measures are quite different from those used in prospective 388 
studies where symptoms such as daily cough or wheeze may be collected. We found that 389 
overall control was significantly better in the FDC group. 390 
It is important to note, that in this population where treatment was stepped up by the 391 
primary care physician, exacerbation rates at baseline were not high: 89% of the population 392 
had no exacerbations in the baseline year; also, SABA prescriptions were moderate, with a 393 
mean of 2.5 puffs of salbutamol or equivalent per day. It is important to note that the data we 394 
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have collected is averaged over the previous year and it may have been that for example 395 
salbutamol use may have been excessive for a short period prompting the Step-up in 396 
treatment. Current UK guidelines suggest that control may be inadequate if SABA use is 397 
more than 3 times per week. This retrospective study cannot establish why it was felt 398 
necessary to increase treatment but we assume that control was felt to be inadequate. 399 
However, because exacerbation rates were relatively low at baseline this may have 400 
influenced our ability to show significant differences in the follow up year. 401 
It is increasingly recognized that asthma is not a single disease entity and different 402 
asthma phenotypes or different underlying gene defects will respond to these treatment 403 
options in different ways. Lemanske et al tried to examine whether patients that responded 404 
better to one or another treatment had any underlying characteristics, and showed that, for 405 
example, those of white race responded better to LABA step-up, and those of black race 406 
were least likely to respond to LTRA (5). Children without a history of eczema may respond 407 
better to LABA step-up, and race appears to differentiate responders to ICS from responders 408 
to LTRA (33). The historic nature of this study prevented further investigation of responders 409 
and non-responders. 410 
 411 
Conclusion 412 
To date, there is a lack of clarity in available evidence in asthma guidelines, 413 
concerning which step-up treatment should be used in children if asthma control is 414 
inadequate on low-dose ICS. The findings of our real-life study suggest that the three main 415 
step-up treatments have beneficial effects in children who are stepped up from 416 
low/moderate-dose ICS, and that the differential effect of any of these treatments is small. All 417 
treatments appear to produce long-term benefit in reducing exacerbation rates in children 418 
with uncontrolled asthma. Changing to FDC may result in better overall asthma control over 419 
LTRA or increased ICS, but this finding needs to be replicated in further studies using real-420 
life datasets. 421 
 422 
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Table I Matched baseline characteristics of children prescribed fixed-dose combination inhalers versus increased dose in inhaled 575 
corticosteroids, and fixed-dose combination inhalers versus add-on leukotriene receptor antagonists 576 
Baseline Characteristic 
FDC versus Increase ICS dose FDC versus LTRA 
FDC (n=971) 
ICS dose increase 
(n=971) 
p value* FDC (n=785) 
Add-on LTRA 
(n=785) 
p value* 
Male sex, n (%) 573 (59) 579 (60) 0.77 453 (58) 482 (61) 0.12 
Age at index date, mean 
(SD)
†
 
9.4 (2.1) 9.4 (2.1) N/A 8.96 (2.2) 8.96 (2.2) N/A 
Recorded comorbidity, n (%)             
Rhinitis diagnosis 227 (23) 234 (24) 0.71 168 (21) 206 (26) 0.03 
Eczema diagnosis 483 (50) 464 (48) 0.38 420 (54) 401 (51) 0.34 
GERD diagnosis/therapy 20 (2) 23 (2) 0.64 15 (2) 25 (3) 0.11 
Year of index date, median 
(IQR) 
2005 (2003–2007) 2004 (2002–2007) <0.001 2006 (2004–2008) 2006 (2004–2008) 0.2 
Average daily SABA dose, 
μg/d mean (SD) 
248 (238) 244 (224) 0.63 246 (219) 256 (255) 0.23 
Average daily ICS dose
α
, μg/d 
mean (SD)
‡
 
175 (155) 203 (201) <0.001 176 (142) 188 (194) <0.001 
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ICS dose prior to Index date,  
Mean (SD) µg/d 
Median (IQR) 
 
361 (127) 
400 (200,400) 
 
363 (134) 
400 (200,400) 
 
0.17 
 
 
372 (188) 
400 (200,400) 
 
368 (168) 
400 (200,400) 
 
0.16 
 
Severe asthma exacerbations, 
ATS/ERS definition
§
 
            
0     n (%)
†
 863 (89) 863 (89) 
0.36 
682 (87) 682 (87) 
0.59 1      n (%) 85 (9) 79 (8) 81 (10) 84 (11) 
≥2   n (%) 23 (2) 29 (3) 22 (3) 19 (2) 
Acute respiratory events, 
mean (SD)
¶
 
0.44 (0.80) 0.48 (0.81) 0.26 0.53 (0.89) 0.63 (1.01) 0.02 
Acute respiratory events, n 
(%)
¶
 
            
0 673 (69) 656 (68) 
0.13 
508 (65) 490 (62) 
0.05 1 206 (21) 204 (21) 185 (24) 175 (22) 
≥2 92 (10) 111 (11) 92 (12) 120 (15) 
Risk-domain asthma control 
achieved, n (%) 
668 (69) 655 (68) 0.452 505 (64) 486 (62) 0.245 
Overall asthma control 
achieved, n (%) 
367 (38) 356 (37) 0.392 277 (35) 270 (34) 0.54 
Murray et al 25 
 
  
Antibiotics with respiratory 
consult, mean (SD) 
0.37 (0.73) 0.41 (0.79) 0.215 0.43 (0.82) 0.57 (0.98) 0.002 
Antibiotics with respiratory 
consult, n (%) 
            
0 722 (74) 702 (72) 
0.2 
559 (71) 519 (66) 
0.003 1 173 (18) 180 (19) 155 (20) 156 (20) 
≥2 76 (8) 89 (9) 71 (9) 110 (14) 
Asthma consultations prior to 
the index date, mean (SD)
#
 
1.99 (1.67) 1.44 (1.42) < 0.001 2.10 (1.73) 1.73 (1.58) < 0.001 
≥1 asthma-related hospital 
admission, n (%) 
4 (0.4) 1 (0.1) 0.22 9 (1) 7 (1) 0.61 
Asthma consultations prior to 
the index date, n (%)
#
 
            
0 172 (18) 297 (31) 
<0.001 
128 (16) 199 (25) 
<0.001 
1 270 (28) 274 (28) 211 (27) 197 (25) 
2 216 (22) 212 (22) 176 (22) 178 (23) 
≥3 313 (32) 188 (19) 270 (34) 211 (27) 
 577 
* Matched cohorts were compared using conditional logistic regression 578 
† matching variable; α Average daily dose ICS over baseline year; ‡ The doses of ICS were standardized to equivalence with fine-particle beclomethasone; 579 
thus, the actual doses of budesonide were used, and doses of extrafine beclomethasone and fluticasone were doubled. § An ATS/ERS severe asthma 580 
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exacerbation is defined as an occurrence of the following: asthma-related hospital admissions or accident and emergency attendance, or an acute course of 581 
oral corticosteroids with evidence of respiratory review; ¶ An acute respiratory event is asthma-related hospital admissions or A&E attendance, or an acute 582 
course of oral steroids with evidence of respiratory review, antibiotics prescribed with evidence of a respiratory review. # Non-specialist primary care 583 
consultation where asthma was recorded 584 
Asthma-related hospitalisations consist of either a definite asthma A&E attendance or a definite asthma hospital admission; or a generic hospitalisation read 585 
code which has been recorded on the same day as a lower respiratory consultation; acute oral corticosteroid use defined as all courses that are definitely not 586 
maintenance therapy, and all courses where dosing instructions suggest exacerbation category group (e.g. 6,5,4,3,2,1 reducing, or 30µg as directed), and all 587 
courses with no dosing instructions, but unlikely to be maintenance therapy with a code for asthma or a lower respiratory event, and/or evidence of a 588 
respiratory consultation; evidence of a respiratory review consists any lower respiratory consultation and, any additional respiratory examinations, referrals, 589 
chest x-rays or events; lower respiratory consultations consist of lower respiratory read codes (including asthma, COPD and LRTI read codes); 590 
asthma/COPD review codes excl. any monitoring letter codes; lung function and/or asthma monitoring. Where ≥1 oral corticosteroid 591 
course/antibiotic/hospitalisation occur within 2 weeks of each other, these events were considered to be the result of the same exacerbation (and will only be 592 
counted once). 593 
ATS/ERS: American Thoracic Society/European Respiratory Society; ED, Emergency Department; FDC, fixed-dose combination; GERD, gastroesophageal 594 
reflux disease; GP, general practice; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β-agonist; N/A, not applicable; OPD, out-patient 595 
department; SABA, short-acting β-agonist; SD, standard deviation 596 
 597 
  598 
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Table II Outcome year results for matched cohorts prescribed fixed-dose combination inhalers versus increased dose in inhaled corticosteroids 599 
(Analysis 1), and fixed-dose combination inhalers versus add-on leukotriene receptor antagonists (Analysis 2)  600 
Outcome 
FDC versus Increase ICS dose FDC versus LTRA 
FDC (n=971) 
ICS dose 
increase 
(n=971) 
p value* FDC (n=785) 
Add-on LTRA p value* 
(n=785)   
Average daily SABA dose, μg/d 
mean (SD) 
233 (234) 315 (281) <0.001 232 (227) 315 (295) <0.001 
Average daily ICS dose, μg/d 
mean (SD)† 
247 (235) 468 (333) <0.001 257 (214) 258 (241) 0.92 
Severe asthma exacerbations, 
ATS/ERS definition 
            
0, n (%) 914 (94) 910 (94) 
0.81 
737 (94) 718 (92) 0.11 
1, n (%) 46 (5) 51 (5) 39 (5) 57 (7)   
≥2, n (%) 11 (1) 10 (1) 9 (1) 10 (1)   
Acute respiratory events, mean 
(SD) 
0.28 (0.66) 0.29 (0.63) 0.78 0.31 (0.70) 0.35 (0.65) 0.23 
Acute respiratory events, n (%)             
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0 772 (80) 757 (78) 
0.615 
614 (78) 573 (73) 0.049 
1 149 (15) 167 (17) 123 (16) 160 (20)   
≥2 50 (5) 47 (5) 48 (6) 52 (7)   
Risk-domain asthma control 
achieved, n (%) 
770 (79) 756 (78) 0.44 614 (78) 569 (73) 0.008 
Overall asthma control achieved, 
n (%) 
445 (47) 317 (33) <0.001 354 (45) 252 (32) <0.001 
Antibiotics with respiratory 
consult, mean (SD) 
0.25 (0.66) 0.24 (0.58) 0.77 0.27 (0.71) 0.29 (0.63) 0.52 
Antibiotics with respiratory 
consult, n (%) 
            
0 796 (82) 788 (81) 
0.92 
627 (80) 608 (77) 
0.19 1 132 (14) 150 (15) 109 (14) 138 (18) 
≥2 43 (4) 33 (3) 40 (5) 39 (5) 
Asthma GP consultations, mean 
(SD) 
1.47 (1.62) 1.20 (1.56) <0.001 1.51 (1.58) 1.50 (1.58) 0.92 
≥1 asthma-related hospital 
admission, n (%) 
4 (0.4) 2 (0.2) 0.42 2 (0.3) 2 (0.3) 1 
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Oral thrush, n (%)
‡
 3 (0.3) 1 (0.1) N/A 1 (0.1) 4 (1) 0.21 
Treatment stability achieved, n 
(%) 
552 (57) 377 (39) <0.001 431 (55) 446 (57) 0.44 
 601 
*Conditional logistic regression 602 
† BDP equivalent dose; ‡ Oral thrush was defined as Read code for oral candidiasis or topical antifungal prescription definitely for treating oral candidiasis 603 
ATS/ERS: American Thoracic Society/European Respiratory Society; FDC, fixed-dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; N/A, not 604 
applicable; SABA, short-acting β-agonist; SD, standard deviation 605 
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Figure I Adjusted rate and odd ratios during outcome year for fixed-dose combination versus 606 
increased dose of inhaled corticosteroid cohorts for primary and secondary outcomes 607 
(Analysis 1)  608 
 609 
FDC, fixed dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; 610 
SABA, short-acting β-agonist. 611 
* Adjusted for: Rhinitis diagnosis/therapy, number of acute oral corticosteroids courses, and 612 
number of asthma consultations (p=0.09); †Adjusted for: Acute oral corticosteroid courses; ‡ 613 
Adjusted for: Antibiotics with evidence of respiratory review and number of asthma 614 
consultations; § Adjusted for: Rhinitis diagnosis/therapy and number of asthma 615 
consultations, and categorized as: 0, 1-150, 151-300, >300µg ; ¶ Adjusted for: Number of 616 
Primary Care Consultations; # Unadjusted p=0.67 (Conditional Logistic Regression) 617 
 618 
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Figure II Adjusted rate and odds ratios during outcome year for fixed-dose combination 619 
versus add-on leukotriene receptor antagonist cohorts for primary and secondary outcomes 620 
(Analysis 2) 621 
 622 
FDC, fixed-dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; 623 
LTRA, leukotriene receptor antagonists; SABA, short-acting β-agonist 624 
*Adjusted for: Number of baseline exacerbations, antibiotics with evidence of respiratory 625 
review, and number of asthma consultations (p=0.116); ); †Adjusted for: Rhinitis 626 
Diagnosis/Therapy and asthma consultations; ‡Adjusted for: Number of baseline antibiotics 627 
with evidence of respiratory review; §Adjusted for: Asthma related OPD Visits, non-asthma 628 
consultations and eczema, and categorised as: 0, 1-150, 151-300, >300µg; ¶Gender, Rhinitis 629 
Diagnosis/Therapy, Baseline antibiotics with evidence of respiratory review and datasource; 630 
# Unadjusted p=0.098 (Conditional Logistic Regression) 631 
 632 
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Clinical Implications 41 
Although guidelines advise a first choice for step-up in children with uncontrolled asthma, 42 
fixed-dose ICS/long-acting β2-agonists (FDC), increased ICS dose, or added leukotriene 43 
receptor antagonists all reduce severe exacerbation rates, but FDC may also improve 44 
asthma control. 45 
 46 
Capsule Summary 47 
Fixed-dose combination inhalers were as effective in reducing severe exacerbations over 12 48 
months for children stepping-up asthma therapy, as increasing inhaled corticosteroid dose or 49 
adding a leukotriene receptor antagonist. 50 
  51 
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ABSTRACT 52 
Background: In children with uncontrolled asthma prescribed low-dose inhaled 53 
corticosteroids (ICS), various step-up options are available: fixed-dose combination 54 
ICS/long-acting β2-agonist (FDC); increasing ICS dose; adding leukotriene receptor 55 
antagonist (LTRA). However, evidence of their relative effectiveness is limited. 56 
Objective: To compare the effectiveness of step-up to FDC in children with asthma versus 57 
increase ICS dose, or LTRA. 58 
Methods: This matched cohort study used UK primary-care databases to study children 59 
prescribed their first step-up treatment to FDC, increase ICS dose, or LTRA. A year of 60 
baseline data was used for matching and identifying confounders. Outcomes over the 61 
following year were examined. The primary outcome was severe exacerbation rate; 62 
secondary outcomes included overall asthma control, derived from databases (no asthma-63 
related admissions/hospital attendances/oral corticosteroids or antibiotics prescribed with a 64 
respiratory review, and average prescribed salbutamol <200 µg/day). 65 
Results: There were 971 matched pairs in the FDC and increase ICS dose cohorts (59% 66 
male; mean age 9.4 years), and 785 in the FDC and LTRA cohorts (60% male; mean age 67 
9.0 years). Exacerbation rates in the outcome year were similar between FDC and increased 68 
ICS (adjusted incidence rate ratio (IRR), 1.09 [0.75–1.59]) and FDC and LTRA (IRR, 1.36 69 
[0.93–2.01]). Increased ICS and LTRA significantly reduced odds of achieving overall 70 
asthma control, compared with FDC (odds ratios 0.52 [0.42-0.64] and 0.53 [0.42-0.66], 71 
respectively) – this was driven by reduced SABA use. 72 
Conclusion: FDC is as effective as increased ICS or LTRA in reducing severe exacerbation 73 
rate, but more effective in achieving asthma control. 74 
 75 
 76 
  77 
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INTRODUCTION 78 
Asthma is the commonest chronic disease in childhood, affecting about 1 in 11 children 79 
in the UK (1). Although most children are well-controlled on low-dose inhaled corticosteroids 80 
(ICS), some will still experience symptoms and exacerbations, and physicians will 81 
recommend a step-up in treatment (2). Current guidelines offer a number of different choices 82 
to physicians, including increasing the dose of ICS and addition of either long-acting beta-83 
agonists (LABA) or leukotriene receptor antagonists (LTRA). Most guidelines, however, tend 84 
to put forward a first choice at this step: The British Thoracic Society guidelines advise the 85 
addition of LABA as FDC as the first step-up option (3); the Global Initiative for Asthma 86 
(GINA) recommends prescribing increased doses of ICS (4).      87 
The reason for these differences in guidance is that research on the comparative 88 
effectiveness of pediatric step-up therapies is limited. In the last few years, the evidence for 89 
which step-up treatment may be best has increased (5-10); in part, by the publication of a 90 
large randomized crossover trial evaluating differential responses over 16 weeks to three 91 
step-up strategies in 182 children aged 6–17 years with uncontrolled asthma on low-dose 92 
ICS (5). However, despite these important recent publications, a Cochrane review of the 93 
evidence published in 2014 still concluded that owing “to the paucity of pediatric trials,” the 94 
authors were “unable to draw firm conclusions about the best adjunct therapy in children” 95 
(11). In addition, until recently, controversy regarding the safety of LABAs may also impacted 96 
on choice (12,13) 97 
Notably, a large multicenter randomized controlled trial in the UK investigating 98 
whether adding LABA or LTRA to low-dose ICS in children could reduce the number of 99 
exacerbations closed early because of lack of recruitment (1412). Despite increasing the 100 
recruitment time, only 63 children were randomized in this study from a target sample size of 101 
450. Recruitment proved difficult in the main because children eligible for the trial were 102 
already prescribed add-on therapy. Consequently, no firm conclusions regarding the study 103 
medications could be drawn. 104 
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Although more evidence is required, large randomized controlled trials not only are 105 
expensive and time-consuming to conduct, but also can be difficult or near impossible to 106 
recruit for. The strengths of “real-world” studies have been highlighted in the “Brussels 107 
Declaration” (1513). A Respiratory Effectiveness Group (REG) study was the first to report 108 
on initial step-up episodes in over 10,000 children in the UK, and the first to describe the 109 
clinical characteristics of children who received different step-up options (1614). Another 110 
REG publication compared the effectiveness of extrafine-particle versus fine-particle ICS for 111 
children initiating or stepping-up ICS therapy and ICS dose step-up with LABA (1715). “Real-112 
world” data about the clinical outcomes of asthma therapy can provide new information and 113 
hypotheses and complement data from controlled trials (1816).  114 
The aim of this large population-based observational study was to compare the 136 
effectiveness of step-up therapies from low-dose ICS in a real-life pediatric population. In 137 
two matched cohorts, we compared the effect of a change to fixed-dose combination (FDC) 138 
versus an increase in ICS dose, and a change to FDC versus add-on LTRA, on asthma 139 
exacerbations and asthma control in the following year. We chose to compare the addition of 140 
LABA as a FDC inhaler rather than separate add on LABA as current global GINA guidelines 141 
recommend the use of combination inhalers (4), our own national guidelines recommend 142 
FDC as the optimal means of adding LABA (19) and we have recently published data from a 143 
similar historical cohort indicating that better asthma control was achieved with FDC inhalers 144 
than with separate inhalers (20). 145 
 146 
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METHODS 147 
Study design  148 
This was a historic observational database study of step-up therapy in children with 149 
asthma, consisting of a baseline year for matching and identifying potential baseline 150 
confounders, preceding the date on which patients received treatment step-up (index date), 151 
followed by an outcome year for evaluating comparative effectiveness (Figure E1). 152 
 153 
Data sources and permissions 154 
Two UK primary care databases were used to source medical and prescribing data, 155 
which include approximately 15% of UK children, and have previously been described in 156 
detail (16,1714,15). Firstly, the Clinical Practice Research Datalink (CPRD), is the world’s 157 
largest database of de-identified records from primary care, and includes longitudinal data 158 
from more than 5 million active medical records from across the UK (17,1821,22). It is a well-159 
validated database that has been used in numerous observational studies (23). Secondly, 160 
the Optimum Patient Care Research Database (OPCRD) is a quality-controlled primary care 161 
research database that contains anonymous routine medical record data and patient 162 
reported outcomes from over 550 practices in the UK (1924). Data was available from 1st 163 
January 1999 through April 2012 for the CPRD, and to December 2012 for the OPCRD. 164 
Patient records were checked to avoid duplication of individuals in the analyses. 165 
The study was conducted to standards recommended for observational research 166 
(2025) and is registered with the European Network of Centres for Pharmacoepidemiology 167 
and Pharmacovigilance (study registration: ENCEPP/SDPP/10483). Data use was approved 168 
by the Independent Scientific Advisory Committee of the CPRD and the Trent Multi-Centre 169 
Research Ethics Committee. The study protocol was approved by the Anonymized Data 170 
Ethics Protocols and Transparency (ADEPT) committee, the independent scientific advisory 171 
committee for the OPCRD.  172 
 173 
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Study population 174 
Included all children were aged 5–12 years with a diagnostic code for asthma or ≥2 175 
asthma prescriptions, or both, in the previous 12 months, were receiving ICS at baseline, 176 
and who had a ≥50% increase in ICS dose, switched to a FDC, or had a LTRA added at the 177 
index date. Included children were registered in the database for at least one year prior to 178 
and following the index date, and had to have received at least one asthma prescription in 179 
addition to the index date prescription during the outcome year. Children were excluded if 180 
they had ever received a diagnosis of any chronic respiratory disease other than asthma, 181 
maintenance oral corticosteroid therapy, multiple step-up therapies at the index date, or a 182 
previous add-on therapy.  183 
 184 
Outcomes 185 
The primary outcome was the number of severe asthma exacerbations in the year 186 
following the index date. Severe asthma exacerbations were defined according to American 187 
Thoracic Society/European Respiratory Society (ATS/ERS) criteria, as an asthma-related 188 
emergency or hospitalization or oral corticosteroids with evidence of respiratory review 189 
(2126).  190 
Secondary outcomes included: 191 
1. Risk-Domain Asthma Control: No emergency or hospital attendance for asthma-related 192 
events; no acute course of oral corticosteroids or antibiotics with evidence of respiratory 193 
consultation.  194 
2. Overall Asthma Control: Risk-Domain Asthma Control and average daily prescribed dose 195 
of ≤200 μg/day salbutamol or ≤500 μg/day terbutaline (equivalent to ≤2 puffs daily of reliever 196 
medication).  197 
3. Treatment stability: Risk-Domain Asthma Control and no preventer treatment change in 198 
the year following the index date.  199 
4. Acute Respiratory Events: Defined as the total number per patient, where an event is 200 
defined as asthma-related emergency or hospitalization or, oral corticosteroids with evidence 201 
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of respiratory review or, antibiotics prescribed with evidence of respiratory review, in the year 202 
following the index date. 203 
Other secondary outcomes including SABA use, prescriptions for oral thrush, and asthma-204 
related hospitalizations, are defined in detail in the Online Repository.  205 
 206 
Statistical analysis 207 
Eligible children from the increase ICS dose and LTRA cohorts were separately 208 
matched (1:1) on key demographic and asthma-related characteristics during the baseline 209 
year to children from the FDC cohort. Matching variables were agreed by the steering 210 
committee a priori as the variables most likely to be associated with asthma outcomes and 211 
therefore potentially confound the results. The final matching variables were: 212 
 213 
1. Index date (+/- 3 years) 214 
2. Age (in years) 215 
3. Any severe asthma exacerbations during the baseline year  216 
4. Prior ICS dose (0-150, 151-250, 251-500, >500 in budesonide equivalent μg doses) 217 
5. Average short-acting β-agonist (SABA) daily doses during the baseline period (0, 1-218 
200, or ≥201 μg salbutamol or equivalent) 219 
Baseline characteristics and outcome variables for unmatched patients were compared 220 
using Chi-square or Mann Whitney tests and, for matched patients, conditional logistic 221 
regression. 222 
The total number of asthma exacerbations and acute respiratory events in the outcome 223 
year were compared between treatment cohorts separately using negative binomial 224 
regression to estimate the incidence rate ratio (IRR) for exacerbations relative to the FDC 225 
group. General estimating equations were used to account for the correlation within matched 226 
pairs. The models used empirical standard errors (to calculate 95% confidence intervals [CI]) 227 
and were adjusted for baseline confounders (2722). The other secondary outcomes were 228 
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compared relative to the FDC group using conditional logistic regression models to estimate 229 
adjusted odd ratios (OR) and 95% CIs. 230 
For all multivariable models, variables showing a trend towards a difference (P < 0.10) 231 
between the matched treatment cohorts at baseline were included as potential confounding 232 
factors along with any strongly predictive variables of the outcome (see Online Repository). 233 
Variables were examined for collinearity and clinical importance and were then removed in a 234 
backwards stepwise procedure, retaining confounding variables with P < 0.1. Analyses were 235 
performed using IBM SPSS Statistics Version 19 (SPSS Statistics, IBM, Somers, NY, USA), 236 
and SAS versions 9.2 and 9.3 (SAS Institute, Marlow, Buckinghamshire, UK). Statistical 237 
significance was defined as P < 0.05.  238 
 239 
RESULTS 240 
Participants 241 
The inclusion/exclusion criteria resulted in 1390 children being selected into the FDC 242 
cohort, 9192 into the increase ICS dose cohort and 1275 into the LTRA cohort (Table E1 243 
and Table E2). Following matching, there were 971 matched pairs in the FDC versus 244 
increase ICS dose analysis (Figure E2), and 785 matched pairs in the FDC versus LTRA 245 
analysis (Figure E3). Table E1 and Table E2 in the Online Repository show the impact of 246 
matching at baseline on unmatched and matched cohorts for demographic variables and 247 
potential confounders. 248 
Children were well-matched on age, sex and comorbidities, although rhinitis was more 249 
common in children stepped-up to LTRA than FDC (Table I). Acute respiratory events and 250 
antibiotics with respiratory consult were more common, and asthma GP consultations less 251 
common, in the LTRA group. Current Average daily dose of ICS in the baseline yearat index 252 
date was significantly lower in those children who were stepped-up to FDC compared with 253 
increase ICS dose (175 µg versus 203 µg) and with LTRA (176 µg versus 188 µg). However, 254 
ICS dose at time of index date was similar between the comparison groups. Overall, no child 255 
was on less than 150µg/day (beclomethasone equivalent) ICS and only 3.9% of all children 256 
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were on >500µg/day (Table E1 & E2). Children who stepped-up to FDC had more GP 257 
consultations for asthma than other groups at baseline.  258 
 259 
Increase ICS dose versus FDC  260 
The percentage of children experiencing one or more exacerbations fell from more 261 
than 11% during baseline to 6% during the outcome year in both cohorts. In the adjusted 262 
analysis, there was no significant difference in exacerbation rates for patients increasing ICS 263 
dose compared with those stepping-up to an FDC (IRR=1.09 [95% CI, 0.75–1.59]; P = 0.09, 264 
Figure I). Similarly, there was no difference in the odds of achieving risk-domain asthma 265 
control (OR=0.91 [95% CI, 0.71–1.16]; P = 0.44). However, children with increased ICS dose 266 
compared with those switching to FDC had significantly lower odds of achieving treatment 267 
stability (0.43 [95% CI, 0.35–0.53]; P < 0.001), and significantly lower odds of achieving 268 
overall asthma control (0.52 [95% CI, 0.42–0.64]; P < 0.001), likely driven by average daily 269 
SABA dose. Patients in the increased ICS dose cohort had a higher mean daily SABA dose 270 
than those in the FDC cohort (315 vs. 233µg; Table II). Similar to the findings at baseline, 271 
asthma GP consultations were still significantly higher in children who stepped-up to FDC 272 
compared with those increasing ICS, though both groups had reduced consultation rates 273 
(Table II). Further outcome differences (e.g. estimates of adherence, ED visits, spacer 274 
prescription) are reported in Table E3, Online Repository. 275 
 276 
Add-on LTRA versus FDC  277 
The percentage of children experiencing one or more exacerbations fell from 13% in 278 
both cohorts during the baseline year to 6% and 8% in the FDC and LTRA cohorts, 279 
respectively, during the outcome year. In adjusted analysis, there was no significant 280 
difference in the rate of severe exacerbations for children stepping-up with add-on LTRA 281 
compared with changing to an FDC (IRR=1.36 [95% CI, 0.93–2.01]; P = 0.12; Table II, 282 
Figure II). Patients adding LTRA had lower odds of achieving risk-domain asthma control, 283 
(OR=0.77 [95% CI, 0.60–1.00]; P = 0.05) and overall asthma control (OR=0.53 [95% CI, 284 
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0.42–0.66]; P < 0.001; Figure II), compared with those switching to FDC, again likely driven 285 
by average daily SABA dose. Patients prescribed LTRA had significantly higher average 286 
daily SABA dosage, compared with FDC (315mg vs 232mg, p<0.001; Table II). Further 287 
outcome differences are reported in Table E3, Online Repository. 288 
 289 
DISCUSSION 290 
Main findings 291 
In this historical, matched cohort study, we found no significant differences in the 292 
year following step-up between either change to FDC versus increased doses of ICS or, 293 
change to FDC versus add-on LTRA, in either the number of, or rate of, severe asthma 294 
exacerbations (ATS/ERS definition). All cohorts achieved a reduction in the number of 295 
exacerbations in the year following step-up. Children changing to FDC were more likely to 296 
achieve asthma control compared to step-up with add-on LTRA or with increased ICS dose. 297 
Children changing to FDC were more likely to achieve treatment stability than those who 298 
increased their ICS dose. Perhaps not surprisingly, those children who stepped-up to FDC 299 
had less average daily SABA use than either of the two comparison groups. This is partly 300 
reflected in the overall asthma control findings. These results were observed after 301 
adjustment for all relevant factors in the data set.  302 
 303 
Interpretation of findings 304 
Very few studies comparing the addition of LABA to ICS with increased doses of ICS 305 
have investigated exacerbations requiring oral corticosteroids as an outcome (5,6,9,10), and 306 
even fewer compared this outcome for the addition of LABA to ICS or LTRA with ICS (5), 307 
despite exacerbations being highlighted as a core outcome for asthma trials in children 308 
(2328). None of these studies use exacerbations requiring oral prednisolone as the primary 309 
outcome of the study, although one large triple crossover study of 182 children included 310 
exacerbations requiring oral corticosteroids along with number of asthma control days and 311 
forced expiratory volume in the first second of expiration (FEV1) as a composite score for the 312 
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primary outcome (5). In this crossover study, more children were likely to respond better to 313 
addition of LABA to ICS than either increased ICS or LTRA, although there was considerable 314 
individual subject heterogeneity in the differential responses to the 3 therapies. Studies 315 
reporting exacerbations as secondary outcomes report very few numbers of exacerbations 316 
and therefore results are difficult to interpret (6, 9, 10). A recent Cochrane review meta-317 
analysis comparing exacerbation rates requiring oral steroid use in those adding LABA to 318 
ICS and those with increased ICS dose, included just 3 studies (6,9,10) (approximately 290 319 
children per group), and found that there was no significant difference in exacerbation rate 320 
between either group (odds ratio, 1.69 [95% CI, 0.85–3.32]) (2429).  321 
Severe asthma exacerbations are relatively rare events, albeit important to patients 322 
and costly to the health service. Very large studies with a long follow-up period are required 323 
to investigate the effect of interventions on exacerbation rates. Real-life studies are ideally 324 
placed to answer such a research question, as typically they are of sufficient size and 325 
duration to assess the impact of exacerbations on health outcomes (2530). However, even 326 
in this large real-life study with a 12-month follow-up period, exacerbation rates were very 327 
low. We found no significant difference between the different step-up treatments in 328 
exacerbation rate. All step-up treatments assessed in this study were associated with 329 
reduced exacerbation rates, suggesting all are effective in reducing exacerbations. 330 
Randomized controlled trials have assessed asthma control in different ways, mostly 331 
with the use of symptom diaries for differing periods of time, documenting daytime and 332 
nighttime symptoms and reliever medication use. Two trials reported no difference in control 333 
between the groups (6,9); one reported better asthma control in the increased ICS group 334 
compared with the addition of LABA group (10) and the other reported, in the form of a 335 
composite score, better outcomes in the addition of LABA group (5). In this real-life 336 
observational study, asthma control cannot be measured in the same way as in prospective 337 
trials. However, the results of our study suggest that control was more likely to be achieved 338 
in children who were stepped-up to FDC, rather than by increasing ICS or by adding LTRA. 339 
When comparing FDC with increased ICS or addition of LTRA, overall asthma control was 340 
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about twice as likely to be achieved, indicating that those individuals stepped-up to FDC had 341 
fewer unscheduled visits and less SABA usage. Although the differential effect between 342 
these step-up changes appears small, this large real-life study complements data from the 343 
largest of the randomized controlled trials cited in this study (5), and supports those 344 
guidelines which advise the addition of LABA as FDC as the first step-up option (3), rather 345 
than those which advise prescribing increased doses of ICS(4).      346 
 347 
Strengths and Limitations 348 
A major strength of our study is the size, which was considerably larger than the 349 
Cochrane meta-analysis (2429). No prospective sample size calculation was estimated for 350 
the study; alternatively, we included all eligible children in the databases from 1st January 351 
1999 who had the required data, to maximize study size. Data prior to 1999 was not 352 
extracted since LTRA and FDC inhalers were not licensed for use in the UK until 1998 and 353 
1999, respectively. Data were extracted from well-maintained databases containing medical 354 
records of approximately 15% of all UK children. Further, approximately 62% of those who 355 
stepped-up to LTRA, and 70% of those stepped-up to FDC, were analyzed, although not all 356 
children who stepped-up were selected. However, we believe that the matched children in 357 
this study were largely representative of those who initiate step-up within primary care 358 
settings in the UK. In addition, the study follows children for a full year following step-up. We 359 
believe the current study complements shorter-term, smaller randomized controlled trials, 360 
and shows the value of real-life research for understanding asthma therapies in children. 361 
We conducted a thorough matching process (2520), resulting in cohorts with similar 362 
baseline characteristics and asthma severity. We adjusted for additional potential 363 
confounding factors, and collected and analyzed follow-up data for a full year after the index 364 
date. However, we cannot exclude the possibility of residual confounding in this study; for 365 
example, the LTRA cohort had more antibiotics but fewer primary care consultations in the 366 
baseline year, perhaps indicating more unstable asthma or different consulting behavior. 367 
There was however, no evidence of significant difference in control at baseline (% of children 368 
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who achieved Risk-domain and Overall control similar in baseline year). The LRTA cohort 369 
also had a higher incidence of rhinitis, which may have impacted on the severity of asthma 370 
symptoms but also may have affected physician choice of step-up treatment. We addressed 371 
this where possible, for example, investigating antibiotics and primary care consultations as 372 
confounders in the multivariate models; they were used as adjusting variables in several of 373 
the outcome models, but were found (where  thought to be unimportant) in the rest. It is also 374 
of note that when examining the year of Index date, patients who stepped up to FDC tended 375 
to have later Index dates than those stepped up to increased ICS. This is probably likely to 376 
be due to the fact that more FDC was used as time progressed as the practitioners became 377 
more familiar with its use (license only granted in children in 1999). However, we cannot 378 
reject the possibility that this may have caused bias within our study; perhaps physicians 379 
who adopted the approach of prescribing this shortly after being granted license were also 380 
more progressive in other ways and managed their patients differently.  381 
We were not able to match on BMI as much of this data was missing from the 382 
dataset, and this may have introduced bias. Socio-economic status and ethnicity was not 383 
available to us. This may also have resulted in bias in our sample. Some incomplete patient 384 
records will have led to some individuals being excluded from this study, which may have 385 
introduced some selection bias. 386 
Conventional methods of measuring asthma control include diary cards, daily SABA 387 
use, and the Asthma Control Test (26,2731,32), but none are considered the “gold 388 
standard.” Due to the historic nature of this study and its large size, we used indirect, 389 
surrogate measures of control derived from accurate markers of healthcare use (both 390 
primary and secondary) for respiratory conditions, prednisolone use, prescription of 391 
antibiotics and SABA use; but it is recognized that some of these measures are quite 392 
different from those used in prospective studies where symptoms such as daily cough or 393 
wheeze may be collected. We found that overall control was significantly better in the FDC 394 
group. 395 
Murray et al 16 
 
  
It is important to note, that in this population where treatment was stepped up by the 396 
primary care physician, exacerbation rates at baseline were not high: 89% of the population 397 
had no exacerbations in the baseline year; also, SABA prescriptions were moderate, with a 398 
mean of 2.5 puffs of salbutamol or equivalent per day. It is important to note that the data we 399 
have collected is averaged over the previous year and it may have been that for example 400 
salbutamol use may have been excessive for a short period prompting the Step-up in 401 
treatment. Current UK guidelines suggest that control may be inadequate if SABA use is 402 
more than 3 times per week. This retrospective study cannot establish why it was felt 403 
necessary to increase treatment but we assume that control was felt to be inadequate. 404 
However, because exacerbation rates were relatively low at baseline this may have 405 
influenced our ability to show significant differences in the follow up year. 406 
It is increasingly recognized that asthma is not a single disease entity and different 407 
asthma phenotypes or different underlying gene defects will respond to these treatment 408 
options in different ways. Lemanske et al tried to examine whether patients that responded 409 
better to one or another treatment had any underlying characteristics, and showed that, for 410 
example, those of white race responded better to LABA step-up, and those of black race 411 
were least likely to respond to LTRA (5). Children without a history of eczema may respond 412 
better to LABA step-up, and race appears to differentiate responders to ICS from responders 413 
to LTRA (3328). The historic nature of this study prevented further investigation of 414 
responders and non-responders. 415 
 416 
Conclusion 417 
To date, there is a lack of clarity in available evidence in asthma guidelines, 418 
concerning which step-up treatment should be used in children if asthma control is 419 
inadequate on low-dose ICS. The findings of our real-life study suggest that the three main 420 
step-up treatments have beneficial effects in children who are uncontrolled onstepped up 421 
from low/moderate-dose ICS, and that the differential effect of any of these treatments is 422 
small. All treatments appear to produce long-term benefit in reducing exacerbation rates in 423 
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children with uncontrolled asthma. Changing to FDC may result in better overall asthma 424 
control over LTRA or increased ICS, but this finding needs to be replicated in further studies 425 
using real-life datasets. 426 
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Table I Matched baseline characteristics of children prescribed fixed-dose combination inhalers versus increased dose in inhaled 580 
corticosteroids, and fixed-dose combination inhalers versus add-on leukotriene receptor antagonists 581 
Baseline Characteristic 
FDC versus Increase ICS dose FDC versus LTRA 
FDC (n=971) 
ICS dose increase 
(n=971) 
p value* FDC (n=785) 
Add-on LTRA 
(n=785) 
p value* 
Male sex, n (%) 573 (59) 579 (60) 0.77 453 (58) 482 (61) 0.12 
Age at index date, mean 
(SD)
†
 
9.4 (2.1) 9.4 (2.1) N/A 8.96 (2.2) 8.96 (2.2) N/A 
Recorded comorbidity, n (%)             
Rhinitis diagnosis 227 (23) 234 (24) 0.71 168 (21) 206 (26) 0.03 
Eczema diagnosis 483 (50) 464 (48) 0.38 420 (54) 401 (51) 0.34 
GERD diagnosis/therapy 20 (2) 23 (2) 0.64 15 (2) 25 (3) 0.11 
Year of index date, median 
(IQR) 
2005 (2003–2007) 2004 (2002–2007) <0.001 2006 (2004–2008) 2006 (2004–2008) 0.2 
Average daily SABA dose, 
μg/d mean (SD) 
248 (238) 244 (224) 0.63 246 (219) 256 (255) 0.23 
Average daily ICS dose
α
, μg/d 
mean (SD)
‡
 
175 (155) 203 (201) <0.001 176 (142) 188 (194) <0.001 
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ICS dose prior to Index date,  
Mean (SD) µg/d 
Median (IQR) 
 
361 (127) 
400 (200,400) 
 
363 (134) 
400 (200,400) 
 
0.17 
 
 
372 (188) 
400 (200,400) 
 
368 (168) 
400 (200,400) 
 
0.16 
 
Severe asthma exacerbations, 
ATS/ERS definition
§
 
            
0     n (%)
†
 863 (89) 863 (89) 
0.36 
682 (87) 682 (87) 
0.59 1      n (%) 85 (9) 79 (8) 81 (10) 84 (11) 
≥2   n (%) 23 (2) 29 (3) 22 (3) 19 (2) 
Acute respiratory events, 
mean (SD)
¶
 
0.44 (0.80) 0.48 (0.81) 0.26 0.53 (0.89) 0.63 (1.01) 0.02 
Acute respiratory events, n 
(%)
¶
 
            
0 673 (69) 656 (68) 
0.13 
508 (65) 490 (62) 
0.05 1 206 (21) 204 (21) 185 (24) 175 (22) 
≥2 92 (10) 111 (11) 92 (12) 120 (15) 
Risk-domain asthma control 
achieved, n (%) 
668 (69) 655 (68) 0.452 505 (64) 486 (62) 0.245 
Overall asthma control 
achieved, n (%) 
367 (38) 356 (37) 0.392 277 (35) 270 (34) 0.54 
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Antibiotics with respiratory 
consult, mean (SD) 
0.37 (0.73) 0.41 (0.79) 0.215 0.43 (0.82) 0.57 (0.98) 0.002 
Antibiotics with respiratory 
consult, n (%) 
            
0 722 (74) 702 (72) 
0.2 
559 (71) 519 (66) 
0.003 1 173 (18) 180 (19) 155 (20) 156 (20) 
≥2 76 (8) 89 (9) 71 (9) 110 (14) 
Asthma consultations prior to 
the index date, mean (SD)
#
 
1.99 (1.67) 1.44 (1.42) < 0.001 2.10 (1.73) 1.73 (1.58) < 0.001 
≥1 asthma-related hospital 
admission, n (%) 
4 (0.4) 1 (0.1) 0.22 9 (1) 7 (1) 0.61 
Asthma consultations prior to 
the index date, n (%)
#
 
            
0 172 (18) 297 (31) 
<0.001 
128 (16) 199 (25) 
<0.001 
1 270 (28) 274 (28) 211 (27) 197 (25) 
2 216 (22) 212 (22) 176 (22) 178 (23) 
≥3 313 (32) 188 (19) 270 (34) 211 (27) 
 582 
* Matched cohorts were compared using conditional logistic regression 583 
† matching variable; α Average daily dose ICS over baseline year;  ‡ The doses of ICS were standardized to equivalence with fine-particle beclomethasone; 584 
thus, the actual doses of budesonide were used, and doses of extrafine beclomethasone and fluticasone were doubled. § An ATS/ERS severe asthma 585 
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exacerbation is defined as an occurrence of the following: asthma-related hospital admissions or accident and emergency attendance, or an acute course of 586 
oral corticosteroids with evidence of respiratory review; ¶ An acute respiratory event is asthma-related hospital admissions or A&E attendance, or an acute 587 
course of oral steroids with evidence of respiratory review, antibiotics prescribed with evidence of a respiratory review. # Non-specialist primary care 588 
consultation where asthma was recorded 589 
Asthma-related hospitalisations consist of either a definite asthma A&E attendance or a definite asthma hospital admission; or a generic hospitalisation read 590 
code which has been recorded on the same day as a lower respiratory consultation; acute oral corticosteroid use defined as all courses that are definitely not 591 
maintenance therapy, and all courses where dosing instructions suggest exacerbation category group (e.g. 6,5,4,3,2,1 reducing, or 30µg as directed), and all 592 
courses with no dosing instructions, but unlikely to be maintenance therapy with a code for asthma or a lower respiratory event, and/or evidence of a 593 
respiratory consultation; evidence of a respiratory review consists any lower respiratory consultation and, any additional respiratory examinations, referrals, 594 
chest x-rays or events; lower respiratory consultations consist of lower respiratory read codes (including asthma, COPD and LRTI read codes); 595 
asthma/COPD review codes excl. any monitoring letter codes; lung function and/or asthma monitoring. Where ≥1 oral corticosteroid 596 
course/antibiotic/hospitalisation occur within 2 weeks of each other, these events were considered to be the result of the same exacerbation (and will only be 597 
counted once). 598 
ATS/ERS: American Thoracic Society/European Respiratory Society; ED, Emergency Department; FDC, fixed-dose combination; GERD, gastroesophageal 599 
reflux disease; GP, general practice; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β-agonist; N/A, not applicable; OPD, out-patient 600 
department; SABA, short-acting β-agonist; SD, standard deviation 601 
 602 
  603 
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Table II Outcome year results for matched cohorts prescribed fixed-dose combination inhalers versus increased dose in inhaled corticosteroids 604 
(Analysis 1), and fixed-dose combination inhalers versus add-on leukotriene receptor antagonists (Analysis 2)  605 
Outcome 
FDC versus Increase ICS dose FDC versus LTRA 
FDC (n=971) 
ICS dose 
increase 
(n=971) 
p value* FDC (n=785) 
Add-on LTRA p value* 
(n=785)   
Average daily SABA dose, μg/d 
mean (SD) 
233 (234) 315 (281) <0.001 232 (227) 315 (295) <0.001 
Average daily ICS dose, μg/d 
mean (SD)† 
247 (235) 468 (333) <0.001 257 (214) 258 (241) 0.92 
Severe asthma exacerbations, 
ATS/ERS definition 
            
0, n (%) 914 (94) 910 (94) 
0.81 
737 (94) 718 (92) 0.11 
1, n (%) 46 (5) 51 (5) 39 (5) 57 (7)   
≥2, n (%) 11 (1) 10 (1) 9 (1) 10 (1)   
Acute respiratory events, mean 
(SD) 
0.28 (0.66) 0.29 (0.63) 0.78 0.31 (0.70) 0.35 (0.65) 0.23 
Acute respiratory events, n (%)             
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0 772 (80) 757 (78) 
0.615 
614 (78) 573 (73) 0.049 
1 149 (15) 167 (17) 123 (16) 160 (20)   
≥2 50 (5) 47 (5) 48 (6) 52 (7)   
Risk-domain asthma control 
achieved, n (%) 
770 (79) 756 (78) 0.44 614 (78) 569 (73) 0.008 
Overall asthma control achieved, 
n (%) 
445 (47) 317 (33) <0.001 354 (45) 252 (32) <0.001 
Antibiotics with respiratory 
consult, mean (SD) 
0.25 (0.66) 0.24 (0.58) 0.77 0.27 (0.71) 0.29 (0.63) 0.52 
Antibiotics with respiratory 
consult, n (%) 
            
0 796 (82) 788 (81) 
0.92 
627 (80) 608 (77) 
0.19 1 132 (14) 150 (15) 109 (14) 138 (18) 
≥2 43 (4) 33 (3) 40 (5) 39 (5) 
Asthma GP consultations, mean 
(SD) 
1.47 (1.62) 1.20 (1.56) <0.001 1.51 (1.58) 1.50 (1.58) 0.92 
≥1 asthma-related hospital 
admission, n (%) 
4 (0.4) 2 (0.2) 0.42 2 (0.3) 2 (0.3) 1 
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Oral thrush, n (%)
‡
 3 (0.3) 1 (0.1) N/A 1 (0.1) 4 (1) 0.21 
Treatment stability achieved, n 
(%) 
552 (57) 377 (39) <0.001 431 (55) 446 (57) 0.44 
 606 
*Conditional logistic regression 607 
† BDP equivalent dose; ‡ Oral thrush was defined as Read code for oral candidiasis or topical antifungal prescription definitely for treating oral candidiasis 608 
ATS/ERS: American Thoracic Society/European Respiratory Society; FDC, fixed-dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; N/A, not 609 
applicable; SABA, short-acting β-agonist; SD, standard deviation 610 
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Figure I Adjusted rate and odd ratios during outcome year for fixed-dose combination versus 611 
increased dose of inhaled corticosteroid cohorts for primary and secondary outcomes 612 
(Analysis 1)  613 
 614 
FDC, fixed dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; 615 
SABA, short-acting β-agonist. 616 
* Adjusted for: Rhinitis diagnosis/therapy, number of acute oral corticosteroids courses, and 617 
number of asthma consultations (p=0.09); †Adjusted for: Acute oral corticosteroid courses; ‡ 618 
Adjusted for: Antibiotics with evidence of respiratory review and number of asthma 619 
consultations; § Adjusted for: Rhinitis diagnosis/therapy and number of asthma 620 
consultations, and categorized as: 0, 1-150, 151-300, >300µg ; ¶ Adjusted for: Number of 621 
Primary Care Consultations; # Unadjusted p=0.67 (Conditional Logistic Regression) 622 
 623 
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Figure II Adjusted rate and odds ratios during outcome year for fixed-dose combination 624 
versus add-on leukotriene receptor antagonist cohorts for primary and secondary outcomes 625 
(Analysis 2) 626 
 627 
FDC, fixed-dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; 628 
LTRA, leukotriene receptor antagonists; SABA, short-acting β-agonist 629 
*Adjusted for: Number of baseline exacerbations, antibiotics with evidence of respiratory 630 
review, and number of asthma consultations (p=0.116); ); †Adjusted for: Rhinitis 631 
Diagnosis/Therapy and asthma consultations; ‡Adjusted for: Number of baseline antibiotics 632 
with evidence of respiratory review; §Adjusted for: Asthma related OPD Visits, non-asthma 633 
consultations and eczema, and categorised as: 0, 1-150, 151-300, >300µg; ¶Gender, Rhinitis 634 
Diagnosis/Therapy, Baseline antibiotics with evidence of respiratory review and datasource; 635 
# Unadjusted p=0.098 (Conditional Logistic Regression) 636 
 637 
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Supplementary methods 
Figure E1. Summary of study design 
 
 
 
 
 
 
 
 
 
 
 
ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonists 
 
Post-hoc sample size 
Power for the primary outcome was conducted post-hoc assuming a Poisson 
distribution and exacerbation rate of 0.18 in the matched FDC group (3,4). In matched add-
on LTRA and increase ICS dose cohorts, we can detect a 37% and 34% reduction in 
exacerbation rates compared to the matched FDC cohort using a two-sided test, 
respectively, with 80% power. 
 
Outcomes 
ATS/ERS (American Thoracic Society/European Respiratory Society) severe asthma 
exacerbations and acute respiratory events are both defined in terms of asthma-related 
hospital admissions, acute course of oral corticosteroids with evidence of respiratory review, 
where asthma-related hospitalisations consist of either a definite asthma accident and 
emergency attendance or a definite asthma hospital admission; or a generic hospitalisation 
Index Prescription Date: 
Date of step-up in treatment 
ICS (any) 
Increased dose of ICS (≥50%) 
Change to fixed-dose combination 
therapy (ICS & LABA) 
Addition of LTRA 
One-year baseline period 
for confounder definition 
One-year outcome period 
for effectiveness 
evaluation 
Repository text, tables, and figures
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Read Code which has been recorded on the same day as a lower respiratory consultation; 
acute oral corticosteroid use defined as all courses that are definitely not maintenance 
therapy, and all courses where dosing instructions suggest exacerbation category group 
(e.g. 6,5,4,3,2,1 reducing, or 30mg as directed), and all courses with no dosing instructions, 
but unlikely to be maintenance therapy with a code for asthma or a lower respiratory event, 
and/or evidence of a respiratory consultation; evidence of a respiratory review consists of 
any lower respiratory consultation and, any additional respiratory examinations, referrals, 
chest x-rays or events; lower respiratory consultations consist of lower respiratory Read 
Codes (including asthma, COPD and Lower Respiratory Tract Infections [LRTI] Read 
Codes); asthma/COPD review codes excluding any monitoring letter codes; lung function 
and/or asthma monitoring.  
Where ≥1 oral corticosteroid course/antibiotic/hospitalisation occur within 2 weeks of 
each other, these events were considered to result from the same exacerbation, and were 
counted once. 
Average daily SABA dose during outcome year was calculated as average number of 
puffs per day over the year multiplied by strength (in μg) and categorized as: 0, 1–150, 151–
300, >300μg.  
Oral thrush was defined as topical anti-fungal prescriptions definitely for oral thrush, 
and/or coded for oral candidiasis. 
 
Supplementary definitions 
The Medication Possession Ratio (MPR) assesses adherence to prescribed therapy. 
In this study, the MPR for prescribed ICS therapy was defined as the number of days’ supply 
of ICS / 365 x 100%. A cut-off of ≥80% is generally strictly used in respiratory studies to 
represent adherent patients, versus ˂80% for non-adherent (1,2). This convention was 
adopted in this study. 
Acute oral corticosteroid use associated with asthma exacerbation treatment, is 
defined as all courses that are definitely not maintenance therapy, and/or all courses where 
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dosing instructions suggest exacerbation treatment (e.g.  6,5,4,3,2,1 reducing, or 30 µg as 
directed), and/or all courses with no dosing instructions, but unlikely to be maintenance 
therapy with a code for asthma or a lower respiratory event, where “maintenance therapy” is 
defined as daily dosing instructions of <10 µg Prednisolone or prescriptions for 1 µg 
Prednisolone tablets. 
Body Mass Index (BMI) is defined as the weight (in kg) divided by the square of the 
height (in meters), and is reported in kg/m2. Age and sex-based BMI centiles were 
categorised, including a ‘missing’ category where BMI was not available. All BMI centile 
values for individuals beyond +/- 5 SDs were excluded as likely outliers.  
The International Obesity Task Force (IOTF) Grade classifies BMI in children aged 2-
18 years as thin, normal weight, overweight or obese, depending on the child's age and sex, 
based on adult BMI cut-offs at 18 years. The BMI range at 18 years and corresponding 
grades are: Very thin <16, Moderately Thin 16 to <17, Thin 17 to <18.5, Healthy 18.5 to <25, 
Overweight 25 to <30, Obese 30+. Both BMI centiles and IOTF Grade were calculated using 
Microsoft Excel add-in lmsGrowth. 
 
Potential confounding variables 
A range of potential confounders have been identified in respiratory research, which 
may impact health outcomes (5). These potential confounders include a range of 
demographic, disease severity, treatment, and comorbid factors. These variables were 
extracted, where available, for all patients.  
Potential confounders examined at (or closest to) the index date: age of patient; sex of 
patient; smoking status of patient; BMI centile; IOFT Grade.  
Potential confounders examined regardless of when they occurred relative to the index 
date: date of first asthma diagnosis (where known); other respiratory or other confounding 
diagnoses, including rhinitis, gastroesophageal reflux disease (GERD), eczema, and cardiac 
disease. 
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Potential confounders examined in the year before the index date: number of primary 
care consultations, both asthma- and non-asthma-related; number of hospital outpatient 
attendances where asthma is recorded as the reason for referral; number of inpatient 
admissions for asthma; number of Emergency Department (ED) attendances for asthma; 
number of ED attendances or inpatient admissions for lower respiratory reasons; number of 
prescriptions for antibiotics with evidence of respiratory review; acute oral corticosteroid use 
associated with asthma exacerbation treatment; prescriptions for other medications that 
might interfere with asthma control: beta-blockers, Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) and paracetamol; number of prescriptions for asthma and/or allergies; SABA daily 
dose; average ICS daily dose; ICS dose at index date. In addition: year of index date; 
previous step-up recorded in the database; time between first asthma prescription and the 
index date (0–1 years, >1 year) database. 
 
Baseline Analysis 
Summary statistics are provided for all baseline and outcome variables, as a complete 
dataset and by treatment groups. For variables measured on the interval or ratio scale, these 
include: sample size (n), percentage non-missing, mean, variance/standard deviation, range 
(minimum/maximum), median, inter-quartile range (25th and 75th percentiles).  
For categorical variables, the summary statistics include sample size (n), range (if 
applicable), count and percentage by category (distribution). Summary statistics highlight 
differences in baseline variable distributions between treatment groups. These differences 
are quantified using conditional logistic regression models. The results of the baseline 
comparisons are presented as p-values. As a conservative approach, differences between 
treatment groups were considered possibly important if p<0.10. Variables meeting this 
criterion were examined for co-linearity and clinical importance to select those used as 
potential confounders in the regression modelling of outcomes.  
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Predictors of outcomes 
Multivariate analyses were carried out using the full dataset to identify baseline 
variables that are predictive (p<0.05) of each outcome variable during the outcome period. 
These were considered as potential confounders when modelling the outcome variables.  
 
Correlations 
Spearman correlation coefficients were calculated between all potential confounders to 
determine strengths of linear relationships between variables. The correlation coefficients 
were considered, in conjunction with clinical interpretation, to identify pairings of variables 
that might present collinearity issues at the modelling stage. In general, collinearity was 
considered an issue for relationships with rank correlation coefficients greater than 0.30.  
 
Effectiveness analysis 
A comparison of treatment cohorts using the matched datasets was conducted making 
necessary minimal adjustments for other baseline confounders. Outcome results are 
provided unadjusted and adjusted for baseline residual confounders for each primary and 
secondary outcome.  
 
Primary outcome analysis 
The total number of asthma exacerbations (ATS/ERS definition) in the outcome period 
was separately compared between cohorts using a negative binomial regression model to 
obtain estimates of the exacerbation rates relative to the FDC cohort. General estimating 
equations were used to account for the correlation within matched pairs. The model uses 
empirical standard errors for more robust confidence intervals and adjusts for potential 
baseline confounders.  
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Secondary outcome analysis  
The total number of acute respiratory events in the outcome period was separately 
compared between cohorts using a negative binomial regression model, and adjusted for 
baseline clinical exacerbations and number of non-asthma related consultations. Secondary 
outcomes risk-domain asthma control, overall asthma control, and treatment stability were 
compared between treatment cohorts using conditional logistic regression models. Each 
secondary outcome was used as the dependent variable with treatment and potential 
confounding factors as independent variables.  
For all multivariate models, those variables that are significantly different or show a 
trend towards a difference (p<0.10) between the treatment groups at baseline were included 
as potential confounding factors along with any strongly predictive variables. Variables were 
examined for co-linearity and clinical importance then removed in a backwards stepwise 
procedure until all confounding variables remaining in the multivariate model had p<0.1. 
Finally, the interaction between sex and treatment was tested for each of the outcomes 
separately in the multivariate models. 
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Supplementary Results 
Figure E2. Patient selection and exact matching (1:1) for ICS dose increase versus fixed-
dose combination ICS/LABA step-up cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Respiratory patients 
in CPRD and OPCRD 
n=898,895 
Patients prescribed  
FDC ICS/LABA n=111,509, or 
ICS increase n=334,693 
Eligible patients aged 5-12 with 
asthma stepped up to 
FDC ICS/LABA: n=1390, or  
ICS increase: n=9192 
(10,582 step-ups) 
 
Totals lost on matching: 
FDC ICS/LABA n=419 
ICS increase n=7591 
Excluded: 
- Patients not on FDC ICS/LABA n=787,386 
- Patients not on ICS increase n=564,202 
 
Patients aged 5-12 at ID  
FDC ICS/LABA n=3948, or 
ICS increase n=13,879 
FDC ICS/LABA inclusion criteria: 
- Aged 5-12 years at ID 
- No LABA prior to FDC ID 
- Received first script for LABA 
between 1990-2011 
- Received ICS script in year before 
ID 
- Asthma diagnostic code or ≥2 
separate asthma scripts in 
baseline year including 1 ICS  
- 1 year of data before and after ID 
 
FDC ICS/LABA inclusion criteria: 
- Patients on FDC ICS/LABA therapy 
 
 
 
 
 
Matching criteria applied: 
-Year of index date ±3 years 
- Same age 
- Number of severe exacerbations in 
year before index date (0, ≥1) 
- Mean ICS daily dose in year before 
ID (0-150, 151-250,  
251-500, >500 μg/day) 
- Mean SABA daily dose in year 
before ID (0, 1-200, >200 μg/day) 
 
Randomize matching 
patients 1:1* 
*Software used to 
randomly pick patients 
 
ICS increase exclusions:  
- No evidence of active asthma n=42 
- Not on active asthma therapy n=604 
- FDC script in year prior to ID n=161 
- <1 year of data before and after ID n=362 
- Diagnosis of chronic respiratory disease 
other than asthma n=25 
- Multiple ICS at date of increase n=455 
- History of cystic fibrosis n=29 
- Maintenance OCS in year prior to ID n=20 
- Add-on therapy in baseline n=1 486 
- Add-on therapy at ID n=286 
 
Total matched patients included 
1:1 uniquely matched pairs: 
FDC ICS/LABA n=971 
ICS increase n=971 
FDC ICS/LABA exclusions: 
- No evidence of active asthma n=7 
- <1 year of data before and after ID 
n=319 
- Diagnosis of chronic respiratory 
disease other than asthma n=9 
- Not on active asthma therapy n=92 
- Received maintenance OCS in 
year prior to ID n=1 
- History of cystic fibrosis n=13 
- Add-on therapy baseline n=330 
- >50% increase or decrease in ICS 
dose at ID n=1768 
- Additional add-on therapy at ID 
n=19 
 
 
ICS increase exclusion criteria: 
- >50% increase as definite dosing 
instructions or via ‘self-management 
program’ rule: BAI/MDI => 2 puffs * 2 daily 
DPI =>1 puff * 2 daily  
- Asthma diagnostic code or ≥2 separate 
asthma scripts in baseline year including 1 
ICS 
 
 
 
ICS increase inclusion criteria: 
- Patients on ICS therapy 
 
FDC ICS/LABA exclusions: 
- First script for FDC not issued 
1990-2011 n=31,538 
- No script for ICS in year before ID 
FDC ICS/LABA n=40,841 
- Not aged 5-12 years at ID  
n=35,182 
 
ICS increase exclusions: 
- First script for LABA not issued 1990-2011 
n=4890 
- No increase in ICS dose n=265,972  
- Not aged 5-12 years at ID n=49,952 
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Patients in the two treatment cohorts were matched on clinically and demographically significant 
characteristics. CPRD, Clinical Practice Research Datalink; FDC, fixed-dose combination ICS/LABA; 
ID, index date; OCS, oral corticosteroid; OPCRD, Optimum Patient Care Research Database; Script, 
prescription. 
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Figure E3. Patient selection and exact matching (1:1) for add-on LTRA versus FDC 
ICS/LABA cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory patients 
in CPRD & OPCRD 
n=898,895 
Patients prescribed  
LTRA n=28,098, or 
FDC ICS/LABA n=111,509 
or LRTA n=28 098 
FDC ICS/LABA inclusion criteria: 
- Patients on FDC ICS/LABA therapy 
 
 
 
 
 
Matching criteria applied: 
- Year of index date ±3 years 
- Same age 
- Number of severe exacerbations in 
year before index date (0, ≥1) 
- Mean ICS daily dose in year before 
index date (0-150, 151-250, 251-
500, >500 μg/day) 
- Mean SABA daily dose in year 
before index date (0, 1-200, >200 
μg/day) 
 
LRTA exclusions:  
- No evidence of active asthma n=6 
- Not on active asthma therapy n=38 
- FDC script in year prior to ID n=104 
- <1 year of data before and after ID n=132 
- Diagnosis of chronic resp. disease other 
than asthma n=4 
- Change in ICS dose at ID n=349 
- History of cystic fibrosis n=1 
- Maintenance OCS in year prior to ID n=2 
- Add-on therapy in baseline n=466 
- Other step-up therapy at ID n=32 
 
Eligible patients aged 5-12 with 
asthma stepped up to 
LTRA n=1275, or  
FDC ICS/LABA n=1390 
(2265 step-ups) 
 
Total lost on matching: 
FDC ICS/LABA n=605 
LRTA n=490 
 
Excluded: 
- Patients not on LTRA n=870,797 
- Patients not on FDC ICS/LABA n=787,386 
Patients aged 5-12 at ID 
LRTA n=2409, or 
FDC ICS/LABA n=3948 
FDC ICS/LABA inclusion criteria: 
- Aged 5-12 years at ID 
- No LABA prior to FDC ID 
- Received first script for LABA 
between 1990-2011 
- Received ICS script in year before 
ID 
- Asthma diagnostic code or ≥2 
separate asthma scripts in 
baseline year including 1 ICS  
- 1 year of data before and after ID 
FDC ICS/LABA exclusions: 
- No evidence of active asthma n=7 
- <1 year of data before and after ID 
n=319 
- Diagnosis of chronic respiratory 
disease other than asthma n=9 
- Not on active asthma therapy n=92 
- Received maintenance OCS in 
year prior to ID n=1 
- History of cystic fibrosis n=13 
- Add-on therapy baseline n=330 
- >50% increase or decrease in ICS 
dose at ID n=1768 
- Additional add-on therapy at ID 
n=19 
 
 
LRTA inclusion criteria: 
- Asthma diagnostic code or ≥2 separate 
asthma scripts in baseline year including 1 
ICS 
 
 
 
LRTA inclusion criteria: 
- Patients on LTRA therapy 
 
FDC ICS/LABA exclusions: 
- First script for FDC not issued 
1990-2011 n=31,538 
- No script for ICS in year before 
index date FDC ICS/LABA  
n=40,841 
- Not aged 5-12 years at index date  
n=35,182 
 
LRTA exclusions: 
- First script for LABA not issued 1990-2011 
n=954 
- No ICS script before and after first LTRA 
n=17,830  
- Not aged 5-12 years at ID n=6905 
 
Randomize matching 
patients 1:1* 
*Software used to 
randomly pick patients 
Total matched patients included 
1:1 uniquely matched pairs: 
LTRA n=785, or 
FDC ICS/LABA n=785 
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Patients in the two treatment cohorts were matched on clinically and demographically significant 
characteristics. CPRD, Clinical Practice Research Datalink; FDC, fixed-dose combination ICS/LABA; 
ID, index date; OCS, oral corticosteroid; OPCRD, Optimum Patient Care Research Database; Script, 
prescription. 
 
 
 
11 
 
Table E1. Unmatched and exact matched (1:1) baseline characteristics of children prescribed fixed-dose combination inhalers versus 
increased dose in inhaled corticosteroids 
Baseline Characteristic 
Unmatched Cohorts (n=10972) Matched Cohorts (n=1942) 
FDC (n=1390) 
Increase ICS Dose 
(n=9192) 
p-value* FDC (n=971) 
Increase ICS Dose 
(n=971) 
p-value
∞
 
Age (years), median (IQR)† 10 (8–11) 9 (7–11) <.001
ↄ
 10 (8–11) 10 (8–11) N/A 
Gender, n (% male)
  
 811 (58) 6206 (60) 0.36 573 (59) 579 (60) 0.78 
Year of Index Date, median (IQR) 2006 (2004–2008) 2001 (1997–2006) <.001
ↄ
 2005 (2003–2007) 2004 (2002–2007) <.001 
Recorded 
comorbidity, n (%) 
  
  
Rhinitis 
diagnosis/ 
therapy‡ 
691 (50) 5723 (55) <.001 481 (50) 531 (55) 0.02 
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Eczema 
therapy§ 
702 (51) 4966 (48) 0.05 483 (50) 464 (48) 0.38 
GERD 
diagnosis/ 
therapy
‡
 
36 (3) 238 (2) 0.48 20 (2) 23 (2) 0.65 
Other medication 
use, n (%)§ 
 NSAIDs 82 (6) 369 (4) <.001 57 (6) 45 (5) 0.22 
 Paracetamol 209 (15) 1529 (15) 0.73 144 (15) 142 (15) 0.90 
Severe asthma 
exacerbations, 
ATS/ERS definition, 
n (%) †,# 
 0 1181 (85) 9317 (90) 
<.001 
863 (89) 863 (89) 
0.36  1 161 (12) 866 (8) 85 (9) 79 (8) 
 >2 48 (3) 226 (2) 23 (2) 29 (3) 
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Risk domain 
asthma control, n 
(%)†† 
Controlled 895 (64) 7064 (68) 0.009 668 (69) 655 (68) 0.45 
Overall asthma 
control, n (%)‡‡ 
Controlled 485 (35) 4201 (40) <.001 367 (38) 356 (37) 0.73 
Acute oral 
corticosteroids, n 
(%)** 
 >1 196 (14) 1021 (10) <.001 105 (11) 104 (11) 0.71 
Prior ICS dose (μg), 
n (%)†, §§ 
 >0–150 0 (0.0) 1507 (15) 
<.001 
0 (0.0) 0 (0.0) 
N/A 
 151–250 257 (19) 7211 (69) 255 (26) 255 (26) 
 251–500 1046 (75) 1596 (15) 695 (72) 695 (72) 
 >501 87 (6) 95 (1) 21 (2) 21 (2) 
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Medication 
Possession Ratio, n 
(%)¶¶ 
 ≥80% 307 (22) 2885 (28) <.001 225 (23) 219 (23) 0.72 
SABA daily dose, n 
(%) (μg)†
 
 
0 28 (2) 705 (7) 
<.001 
19 (2) 19 (2) 
N/A >0-200 685 (49) 5390 (52) 495 (51) 495 (51) 
>201 677 (49) 4314 (41) 457 (47) 457 (47) 
Antibiotics with 
respiratory consult, 
n (%) 
  390 (28) 2838 (27) 0.53 249 (26) 269 (28) 0.28 
Oral thrush, n (%)##   10 (1) 73 (1) 0.94 6 (1) 8 (1) 0.59 
* Chi-Square; ∞ Conditional logistic regression; ↄ Mann Whitney; † Matching variables; ‡ Read Code at any time and/or prescription during baseline or 
outcome analysis period; § Prescriptions received during the 1 year prior to IPD or at IPD; ¶ Read Code at any time; # An ATS/ERS severe asthma 
exacerbation is defined as an occurrence of the following: asthma-related hospital admissions or accident and emergency attendance; or an acute course of 
oral corticosteroids with evidence of respiratory review; ** Acute oral corticosteroid use defined as all courses that are definitely not maintenance therapy, and 
all courses where dosing instructions suggest exacerbation category group (e.g. 6,5,4,3,2,1 reducing, or 30 µg as directed), and all courses with no dosing 
instructions, but unlikely to be maintenance therapy with a code for asthma or a lower respiratory event, and/or evidence of a respiratory consultation; †† 
Asthma control defined as absence of the following: asthma-related hospital admissions or accident and emergency attendance; or out-patient department 
attendance; and an acute course of oral corticosteroids with evidence of respiratory review, and antibiotics prescribed with evidence of respiratory review; ‡‡ 
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Overall asthma control is defined as asthma control plus average daily dose of ≤200 µg salbutamol / ≤500 µg terbutaline; §§ beclometasone dipropionate 
equivalent doses; ¶¶ Medication Possession Ratio is defined as the number of days supply of ICS/365*100%; ## Diagnosis for candidiasis and/or anti-fungals 
definitely for oral thrush  
ATS/ERS: American Thoracic Society/European Respiratory Society; FDC, fixed-dose combination; GERD, gastroesophageal reflux disease; ICS, inhaled 
corticosteroid; IQR, interquartile range; LABA, long-acting β-agonist; N/A, not applicable; NSAIDS, nonsteroidal anti-inflammatory drugs; SABA, short-acting 
β-agonist; SD, standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Table E2. Unmatched and exact matched (1:1) baseline characteristics of children prescribed fixed-dose combination inhalers versus add-on 
leukotriene receptor antagonists 
Baseline Characteristic 
Unmatched Cohorts (n=2665) Matched Cohorts (n=1570) 
FDC (n=1390) Add-on LTRA (n=1275) 
p-
value* 
FDC (n=785) Add-on LTRA (n=785) 
p-
value
∞
 
Age (years), median (IQR)† 10 (8–11) 8 (6–10) <.001
ↄ
 9 (7–11) 9 (7–11) N/A 
Gender, n (% male)
  
 811 (58) 768 (60) 0.32 453 (58) 482 (61) 0.12 
Year of Index Date, median (IQR) 2006 (2004–2008) 2007 (2004–2008) <.001
ↄ
 2006 (2004–2008) 2006 (2004–2008) 0.20 
Recorded 
comorbidity, n (%) 
  
  
Rhinitis 
diagnosis/ 
therapy‡ 
691 (50) 727 (57) <.001 401 (51) 452 (58) 0.00 
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Eczema 
therapy§ 
702 (51) 662 (52) 0.46 420 (54) 401 (51) 0.34 
GERD 
diagnosis/ 
therapy
‡
 
36 (3) 41 (3) 0.34 15 (2) 25 (3) 0.12 
Other medication 
use, n (%)§ 
 NSAIDs 82 (6) 79 (6) 0.75 47 (6) 52 (7) 0.61 
 Paracetamol 209 (15) 190 (15) 0.92 127 (16) 118 (15) 0.53 
Severe asthma 
exacerbations, 
ATS/ERS definition, 
n (%) †,# 
 0 1181 (85) 1105 (87) 
0.39 
682 (87) 682 (87) 
0.59  1 161 (12) 135 (12) 81 (10) 84 (11) 
 >2 48 (3) 35 (3) 22 (3) 19 (2) 
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Risk domain 
asthma control, n 
(%)†† 
Controlled 895 (64) 751 (59) 0.004 505 (64) 486 (62) 0.25 
Overall asthma 
control, n (%)‡‡ 
Controlled 485 (35) 442 (35) 0.90 277 (35) 270 (34) 0.54 
Acute oral 
corticosteroids, n 
(%)** 
>1 196 (14) 160 (13) 0.24 95 (12) 98 (13) 0.41 
Prior ICS dose (μg), 
n (%)†, §§ 
 >0–150 0 (0.0) 41 (3) 
<.001 
0 (0.0) 0 (0.0) 
N/A 
 151–250 257 (19) 619 (49) 248 (32) 248 (32) 
 251–500 1046 (75) 535 (42) 490 (62) 490 (62) 
 >501 87 (6) 80 (6) 47 (6) 47 (6) 
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Medication 
Possession Ratio, n 
(%)¶¶ 
 ≥80% 307 (22) 303 (24) 0.30 186 (24) 165 (21) 0.17 
SABA daily dose, n 
(%) (μg)†
 
 
0 28 (2) 48 (4) 
0.02 
9 (1) 9 (1) 
N/A >0-200 685 (49) 640 (50) 391 (50) 391 (50) 
>201 677 (49) 587 (46) 385 (49) 385 (49) 
Antibiotics with 
respiratory consult, 
n (%) 
  390 (28) 467 (37) <.001 226 (29) 266 (34) 0.02 
Oral thrush, n (%)##   10 (1) 10 (1) 0.85 5 (1) 6 (1) 0.74 
* Chi-Square; ∞ Conditional logistic regression; ↄ Mann Whitney; † Matching variables; ‡ Read Code at any time and/or prescription during baseline or 
outcome analysis period; § Prescriptions received during the 1 year prior to IPD or at IPD; ¶ Read Code at any time; # An ATS/ERS severe asthma 
exacerbation is defined as an occurrence of the following: asthma-related hospital admissions or accident and emergency attendance; or an acute course of 
oral corticosteroids with evidence of respiratory review; ** Acute oral corticosteroid use defined as all courses that are definitely not maintenance therapy, and 
all courses where dosing instructions suggest exacerbation category group (e.g. 6,5,4,3,2,1 reducing, or 30 µg as directed), and all courses with no dosing 
instructions, but unlikely to be maintenance therapy with a code for asthma or a lower respiratory event, and/or evidence of a respiratory consultation; †† 
Asthma control defined as absence of the following: asthma-related hospital admissions or accident and emergency attendance; or out-patient department 
attendance; and an acute course of oral corticosteroids with evidence of respiratory review, and antibiotics prescribed with evidence of respiratory review; ‡‡ 
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Overall asthma control is defined as asthma control plus average daily dose of ≤200 µg salbutamol / ≤500 µg terbutaline; §§ beclometasone dipropionate 
equivalent doses; ¶¶ Medication Possession Ratio is defined as the number of days supply of ICS/365*100%; ## Diagnosis for candidiasis and/or anti-fungals 
definitely for oral thrush  
ATS/ERS: American Thoracic Society/European Respiratory Society; FDC, fixed-dose combination; GERD, gastroesophageal reflux disease; ICS, inhaled 
corticosteroid; IQR, interquartile range; LABA, long-acting β-agonist; N/A, not applicable; NSAIDS, nonsteroidal anti-inflammatory drugs; SABA, short-acting 
β-agonist; SD, standard deviation 
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Table E3. Outcome year results for matched (1:1) cohorts prescribed fixed-dose combination inhalers versus increased dose in inhaled 
corticosteroids, and fixed-dose combination inhalers versus add-on leukotriene receptor antagonists 
Outcome 
FDC versus ICS Dose Increase FDC versus LTRA 
FDC 
(n=971) 
ICS dose 
increase 
(n=971) 
p-value* FDC 
(n=785) 
Add-on LTRA 
(n=785) 
p-value* 
≥1 asthma-related ED attendance,  
n (%) 1 (0.1) 2 (0.2) 
0.57 1 (0.1) 3 (0.4) N/A 
≥1 asthma-related OPD visit, n (%) 4 (0.4) 4 (0.4) 1.00 3 (0.4) 10 (1) 0.06 
1 acute course of oral corticosteroids,  
n (%) 41 (4) 50 (5) 
0.68 
36 (5) 53 (7) 
0.12 
≥2 courses of oral corticosteroids,  
n (%) 11 (1) 9 (1) 9 (1) 10 (1) 
SABA inhalers, mean (SD) 4 (4) 6 (5) <0.001 4 (4) 6 (5) <0.001 
Hours/day β-agonist coverage,  
median (IQR)
 †   
 11 (7–16) 2 (1–4) 
<0.001 10 (7–16) 2 (1–4) <0.001 
Daily ICS dose, median (IQR) 197 (132–307) 384 (219–581) <0.001 197 (132–329) 219 (110–329) 0.92 
% Adherence to ICS, median (IQR) 71 (48–100) 65 (42–95) 0.01 74 (49–100) 82 (55–109) 0.001 
Medication possession ratio ≥80% for ICS, 
n (%) 319 (33) 298 (31) 
0.29 279 (36) 280 (36) 0.95 
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Controller-to-total medication ratio ≥0.5, n 
(%) 793 (82) 679 (70) 
<0.001 645 (82) 670 (85) 0.08 
Change in therapy (any time), n (%)       
Increase in ICS dose (any time), n (%) 239 (25) 411 (42) <0.001 197 (25) 85 (11) <0.001 
Additional therapy (any time), n (%) 98 (10) 156 (16) <0.001 81 (10) 116 (15) <0.001 
Spacer prescription, n (%) 167 (17) 209 (22) 0.01 138 (18) 184 (23) 0.004 
* Conditional logistic regression 
† Adjusted for: Adherence to ICS, defined as number days per pack=number of actuations per pack/Number of actuations per day, Total Pack Days=Σ 
(number days per pack), refill rate %=(total pack days/365) * 100; Adjusted p<0.001 (Conditional logistic regression); 
ED, emergency department; FDC, fixed-dose combination; GP, general practice; ICS, inhaled corticosteroid; IQR, interquartile range; LTRA, leukotriene 
receptor antagonist; N/A, not applicable; OPD, outpatient department; SABA, short-acting β-agonist 
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